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ABSTRACT 
Rationale: Cardiovascular disease (CDV) is the leading cause of mortality and 
morbidity in Canada. Mortality from cardiovascular disease is higher in Newfoundland 
and Labrador (NL) than other Canadian provinces. Gender differences in the treatment of 
and assessment of CVD have been repeatedly demonstrated in clinical trials. 
Objective: 1) To determine the existence and impact of gender bias in the treatment of 
Acute Myocardial Infarction (AMI) in NL. 2) To determine if male gender is associated 
with inappropriate use of surgical revascularization in NL. 
Design: Two observational studies: 1) Prospective cohort study; 2) Cohort study with 
retrospective data collection. 
Setting: University based tertiary referral center in St. John's, NL. 
Participants: 1) AMI patients admitted between May 24, 1990 and June 30, 1993 and 
followed for 3 years. 
2) Patients referred for Coronary Angiography (CA) between April!, 1994 and March 
31, 1995 who subsequently underwent Coronary Artery Bypass Grafting (CABO). 
Measurements: 1) The gender rates of risk factors, post-MI complications, CA, 
pharmacologic interventions, CABO, Percutaneous Transluminal Coronary Angioplasty 
(PTCA), functional class assessment uSing Goldman scales and mortality for three years 
following AMI were compared. 
2) CAD risk factors, angina severity, coronary anatomy, medical therapy, CABO 
indication, appropriateness and necessity of CABO and operative risk and post operative. 
complications were compared by gender. I 
Results: 1) During the AMI admission 9.4% of women compared to 3.9% of men had 
recurrent MI (p=0.04), 12.6% of women and 7.4% of men died (p=0.03). With the 
exception of heparin (6'7'»/o male vs. 58% female p = 0.02), pharmacologic intervention 
was comparable in men and women. CA was performed in 31 % of women and 41.9% of 
men (p = 0.007). Men were more likely to be revascularized during the AMI admission 
(19.3 vs. 12.2, p= 0.02) but there was no gender difference inrevascularization up to 
three years post-MI. Multiple logistic regression analysis (MLR), which included 
demographic and clinical characteristics, revealed that male sex was a strong predictor of 
CA and revascularization post-MI. During follow-up women consistently reported a 
statistically significant reduced functional capacity. Survival analysis revealed that 
women had significantly reduced likelihood of survival (p=0.004) independent of age and 
Angiotensin Converting Enzyme (ACE) inhibitor therapy. 
v 
2) Ahhough there was no gender difference in angiographic findings of patients referred 
for CABG, 88.5% ofwomen compared to 78.90,4, of men were referred for CA due to 
Class IV angina (p=0.006) and 49.9% of women versus 30.1% of men were at 
moderately to very high operative risk (p=O.OOO). CABO was deemed highly appropriate 
in 96.8% of women versus 99.5% of men (p=0.066) and highly necessary in 92.7% of 
women versus 94.2% of men (p=0.66). 
Conclusions: 1) In Newfoundland and Labrador, Canada, despite more complicated 
post-MI courses, women were as likely as men to receive standard pharmacologic 
intervention but significantly less likely to undergo CA and revascularization following 
AMI. 
2) Furthermore women referred for CABO had more advanced and severe CHD than 
men. It is possible that gender bias in the utilization of coronary revascularization may 
contn'bute to excess CHD mortality observed in women. 
Caution must be exercised in generalizing the results of these studies of highly selected 
populations to the overall population ofNL. 
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PREFACE 
The first data set analyzed for the purpose of satisfying the requirements for this thesis 
was collected :from 1990 to 1995 (Newfoundland and Labrador Myocardial Infarction 
study) and the second was collected in 1996 (Newfoundland and Labrador Coronary 
Artery Bypass Grafting Study). These data sets may be considered by some to be dated. 
However, since there are no other published data offering discussion of gender bias in the 
treatment of cardiovascular disease, as it relates to the population ofNewfoundland and 
Labrador, this thesis serves to fill a significant void in this area. Additionally, regardless 
of the age of the data sets analyzed, the requirements of the thesis may be fulfilled in the 
analysis and interpretation of these data sets. 
1 Introduction 
1.1 THE BURDEN OF CARDIOVASCULAR ILLNESS 
Nearly twice as many women die from cardiovascular disease (CVD) in North America 
than all forms of cancer comb~ yet only a very small percentage of women perceive 
heart disease to be a significant health threat (Legato, Padus & Slaughter, 1997; Heart and 
Stroke Foundation of Ontario, 2000). Despite overwhelming evidence to the contrary, 
many physicians still believe CVD to be primarily a disease of men and are not sufficiently 
attentive to the potential burden of CVD in. females (Legato et al, 1991). 
Mortality from CVD in. Canada is declining (Merkatz, Temple, Sobel et al, 1993; Fallen, 
Armstrong, Cairns et al, 1991). Most of this decline is due to fewer deaths from 
myocardial infarction (MI) and the reduction is more pronounced in. men (Brophy, 1991). 
Cardiovascular disease remains the leading cause of death among Canadians (Heart and 
Stroke Foundation of Canada, 1996). 
Cardiovascular disease is the leading cause of hospitalization among women in. Canada, 
despite the fact that women develop coronary artery disease (CAD) less :frequently and 
later in. life than men (Lerner & Kannel, 1986). In the F ASTRAK database, a national 
registry of acute coronary syndromes, women accounted for almost one third of patients 
admitted with acute myocardial infarction (AMI) in. 1998 (Heart and Stroke Foundation 
of Canada, 1999). In 1992, more than 39,000 men and nearly 37,000 women died from 
CVD. In Canada, 41 %of deaths in. women and 37% of deaths in. men resulted from 
cardiovascular related diseases in. 1993 (Heart and Stroke Foundation of Canada, 1995). 
Independent of age and other contnbuting factors, Ontario women were shown. to have 2-
3 % higher hospital mortality than men (Naylor & Chen, 1994). In addition, significant 
costs associated with morbidity and mortality related to CVD in Canada. 
In 1998 the total cost of illness in Canada was similar for males and females ($62.9 billion 
versus $57.5 billion) (Health Canada, 2002). These estimates include direct costs, 
(hospital care expenditures, physician care expenditures and drug expenditures) and 
indirect costs (those related to mortality and long- and short-term disability). The 
distribution of cost-by-cost component varies oonsiderably so that 32:8 %of the total cost 
fur males and 42.5% of the total cost for females is allocated to direct costs while the 
remainder is allocated to indirect costs. The per capita direct costs of illness are essentially 
equal for all Canadian provinces and territories (Health~ 2002). 
In 1998, direct costs attributable to CVD were approximately $6.81 billion dollars while 
the indirect costs were approximately $11.65 billion dollars (Health Canada, 2002). Direct 
costs ofCVD in Canadian women in 1993 were approximately $3.23 billion and indirect 
costs were $4.72 billion (Heart and Stroke Foundation of~ 1996). The 
measurement of indirect costs of CVD in women does present some difficulty, as women 
represent a sizeable unpaid workforce potentially resulting in falsely low estimates (Heart 
and Stroke Foundation of Canada, 1996; Health Canada, 2002). 
Two studies have estimated that the annual cost ofCVD in Canada exceeds 19.7 billion 
. dollars (Moore, Mao, Zhang et al, 1997; Chan, Coyote & Heick, 1996). A third Canadian 
report demonstrated that in 1998 the total cost of illness attributable to CVD was 18.5 
billion dollars. This accounted for 11.6% of the overall cost of illness in 1998. The costs 
have remained relatively stable since 1986 (Health Canada, 2002). 
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In Canada, mortality related to CVD is influenced by geography and age-standardized 
female mortality seems to follow an east-west gradient, with higher rates in Newfoundland 
and Labrador (NL) women (241 per 1 00,000) and lower rates in British Columbia (BC) 
women (164 per 100,000) (Heart and Stroke Foundation of Canada, 1999). 
Data from the Newfoundland & Labrador Center for Health Information show that, in NL 
in the :last six years, there has been a dramatic increase in the annual number of patients 
having coronary angiograms (CA), coronary artery bypass grafts (CABO's) and 
percutaneous transluminal coronary angioplasties (PTCA's). For example 1,363 CA's, 346 
CABO's and 307 PTCA's were performed in 199511996, while 2001 CA's, 553 CABO's 
and 502 PTCA's were performed in 2000/2001. The number ofCA has remained 
constant since 1998 while the number of CABO's continues to increase annually and the 
number ofPTCA's seems to have peaked in 1998/1999 and fallen in the following two 
years (D. MacDonald, Director, Product Development Division, Newfoundland and 
Labrador Center for Health Information, personal communication, January 17, 2003). 
Gender distribution remains the same for all procedures during that six-year period, with 
approximately 70 % of all CA and PTCA's and 75 % of all CABO's performed on men. 
When gender is additionally divided by ages ofless than 70 years, age 70 to 74 years and 
age greater than 74 years, it becomes clear that the greatest differences in gender 
distnbution of procedures is seen in the younger age groups. This is particularly evident 
in the group over 74 years where gender distnbution of CA and PTCA is approximately 
equal. Gender distnbution of CABO in this age group varies widely from 56 % male to 79 
% male but consistently more males than females receive CABO (D. MacDonald, personal 
communication, January 17, 2003). 
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Life expectancy of Canadians is gradually increasing. Women outlive men by an average 
of7.5 years (Gurwitz, Nananda & Avron, 1992). This results in increasing numbers of 
women with coronary heart disease. Since it appears that recognized treatments are 
generally underutilized in women, and that women are disproportionately affected by age-
based rationing of health care dollars (Jecker, 1991) female access to these treatments 
requires particular attention. 
As this will impact delivery of health care, appropriate use of recognized treatments for 
coronary heart disease requires further examination. In Canada, Newfoundland and 
Labrador is disproportionately affected by morbidity and mortality as well as increasing 
use ofhealth care resources to treat CVD in women. Consequently, assessment of 
gender-based differences in the management of CVD in Newfoundland and Labrador is of 
utmost importance. 
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2 Bias 
2.1 BIAS IN CLINICAL RESEARCH 
For hundreds of years scientists have attempted to assess the value of therapies, however, 
it was not until1938 that the first law, requiring establishment of drug safety prior to 
marketing, was passed (N~ 1968). In 1979, publication of the Belmont Report, a 
comprehensive review of human experimentation, exploring ethical and human rights 
considerations, resuhed in greater protection for human research subjects (The Belmont 
Report, 1978) .. Considering the fairly recent development of standards in performing 
clinical trials, it is not surprising that the science of clinical trials is imperfect and that 
problems such as bias have not been eliminated from the process. 
Bias in clinical research introduces systematic error that may prejudice the outcome in 
such a way that resuhs are no longer valid. Bias may be introduced at any phase in 
development, execution, or interpretation of a clinical trial (Spilker, 1991; Sachett, 1979). 
Since differences in treatment outcome may occur. due to chance, treatment effect, or bias, 
recognition, avoidance, and minimization ofbias should be a primary concern for all 
investigators from inception of a clinical question to publication of the data. Proper 
execution and accurate interpretation of significance tests should be able to determine if 
differences can be explained by chance. Elimination of all possible systematic error should 
effectively reduce the possibility that differences in treatment are due to bias. 
Sackett maintains that bias can occur at all stages of clinical trials. He has catalogued 
fifty-seven biases and provided a definition and an example for many (Sachett, 1979). 
Following his work in 1979, he and others have attempted to descn"be new, or redefine 
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old, biases and develop standards for preventionofbias in clinical trials (Spilker, 1991). 
It is generally agreed that the best way to prevent bias is to be knowledgeable about the 
sources of bias and methods of prevention. Retrospective case-control or cohort studies 
are most susceptible to introduction ofbias. Prospective randomized controlled trials 
provide the greatest assurance against bias. However these trials are not always possible 
or practical and are not entirely exempt from the influence ofbias. Spilker provides an 
excellent resource guide for reducing bias in this type oftrial (Spilker, 1991). 
Even results from prospective randomized, controlled clinical trials are only generalizable 
to populations similar to those under study. Restrictive inclusion criteria produce a 
homogeneous study population but may restrict the ability to extrapolate study results to 
patients with characteristics that differ from the population studied. Therefore, selection 
of study samples must be broad enough to be applicable to the population of interest. 
The majority ofbiases detailed in Sackett's catalogue ofbiases fall under the heading of 
bias in selecting the study sample (Sachett, 1979). This provides evidence to the 
complexity of selection bias in clinical trials and makes it easy to see how selection criteria 
can influence study results. 
Referral of subjects to clinical facilities may also distort study conclusions if study samples 
are selected from only one institution. Typically the most complex cases are referred to 
facilities equipped to handle them (Greenberg, Daniels, Flanders et al, 1996). The unique 
geography, as well as population and bealthcare resource distribution ofNewfoundland 
and Labrador has the potential to introduce bias in the assessment and treatment of 
patients in this province. Concentration of cardiac facilities and specialists in one tertiary 
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referral centre introduces selection biases into cardiac patient referral in this province. 
Clinicians can feel secure in evaluating treatment modalities and make objective inferences 
based on the outcome of clinical trials only when every effort has been made to eliminate 
bias. Despite many advances in design methodologies, publication of contradictory results 
from clinical trials propagates skepticism among clinicians and investigators alike (Horwitz 
and Feinstein, 1979). This may be partly responsible for failure to implement clinical trial 
results into medical practice and, in particular, failure to implement the results of cardiac 
trials into standard treatment for female cardiac patients. Newfoundland and Labrador 
offers a unique opportunity to assess the impact of selection bias on treatment of cardiac 
disease in women. 
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2.2 GENDER BIAS IN CLINICAL RESEARCH 
Women~s cardiovascular health needs are poorly understood because less clinical 
information is available regarding coronary artery disease in women. Treatments, which 
have proven to be safe and efficacious in male populations, may not have the same benefits 
in female populations. Failure to conduct gender specific research may result in ill-defined 
criteria for diagnosis and treatment ofheart disease in women (Levy, 1991). 
Recruitment may bias trial data if subjects differ greatly :from others with the disease. This 
is known as selection bias and is the most likely explanation. for exclusion of women :from 
clinical trials. Women have traditionally been underrepresented in clinical trials ofCVD 
and data have not been analyzed by gender (Douglas, 1986; Horton, 1994). The most 
cited explanations for exclusion of women :from clinical trials includes fear of 
teratogenicity, hormonal :fluctuations, cardiovascular protection by estrogen and low 
incidence of measured outcomes (Levy, 1991; Fetters, Peterson, Shaw et al, 1996; 
Horton, 1994; Ryan, Anderson, Antman et al, 1996). The claim of cardiovascular 
protection by estrogen has been refuted by Heart and Estrogen/progestin Replacement 
Study (HERS) investigators who noted increased cardiovascular events in the first year of 
hormone rep1acement therapy (Hulley, Grady, Bush et al, 1998). Others note that it is 
difficult to recruit women into clinical trials (Legato, 1994); Johnson and colleagues 
however, report that women were as likely as men to consent to follow·up in 
observational studies (Johnson, Goldman, Orav, et al, 1996). 
Trials with age-based exclusions have fewer female subjects than those without. The 
results of one study suggest that over 60 % of randomized controlled clinical trials ofMI 
treatments exclude persons over 75 years of age, and up to 50 % exclude persons over 70. 
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Age-based exclusions in clinical trials have increased significantly since 1979. Since 
women comprise the 'largest percentage of the popu1ation over 75 years~ age-based 
exclusions in CVD trials eliminate women :from clinical studies of a disease process by 
which they are disproportionately affected in old age (Gurwitz, 1992; Jecker, 1991). In 
addition, five percent of studies exclude women totally, and 7.5 % exclude women of 
childbearing potential because of contraceptive requirements for inclusion (Cain, Lowell, 
Thorndyke et al, 2000). 
The majority ofMI related deaths occur in patients over 65 years of age. Sixty-four 
percent of those who die of acute myocardial infarction over the age of 85 years are 
female. By virtue of this :fuct, age bias equates to gender bias. The elderly are more likely 
to be excluded :from trials using thrombolytic therapy or invasive procedures (Ourwitz, 
1992; Jecker, 1991 ). Reluctance to use these treatments in the elderly puts the popuJation 
most affected by the disease at a decided medical disadvantage. 
Women's health issues have received increasing attention since the 1980's. Following the 
report of a Public Health Service Task Force on Women's Health Issues in 1985, The US 
National Institutes of Health (NIH) strengthened its policies regarding inclusion of women 
and minorities in clinical trials (Levy, 1991; Manolio & Har~ 1993; Healey, 1991, 
JAMA). Following adoption of the Women's Health Equity Act in 1990, the Office of 
Research on Women's Health (ORWH) was established at the NIH (Beery, 1995) and is 
responsible for the administration of three Centers of Excellence in Women's Health 
Research. As part of its mandate, ORWH is charged with ensuring that women participate 
in clinical research, and that trial data is analyzed and reported by gender to ensure that 
differences in drug safety and efficacy are identified (Becker, 1995). In 1993, the Food 
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and Drug Administration (FDA) revised its policy to ensure that women of childbearing 
potential who use accepted methods of birth control are included in early phase clinical 
trials (Merkatz et al, 1993). 
The Women's Health Initiative (WHI), one of the first projects to be undertaken by the 
NIH, is a fifteen-year prospective study (including 160,000 women) that will assess the 
effect ofhormone replacement therapy, aspirin, antioxidant therapy, low fat diet, and 
lifestyle changes on cardiovascular and other diseases (Legato, 1994; Becker, 1995). 
In Canada, a Federal/ Provincial/ Territorial Advisory Committee on Health Infostructure 
was convened at the Conference of Deputy Ministers ofHealth in 1997. This group 
provided a framework for developing policies and programs pertaining to.sharing 
information on the health of all Canadian This stimulated national discussion regarding 
consolidation of major health databases and development of a central registry of all 
Canadian clinical trials. This would facilitate review of data relevant to women's health 
and results of clinical trials that include female subjects (Kanzanjian, 1998). 
Although Canadjan researchers are aware of the importance of including women into 
clinical trials, analysis of data by sex is declining (Marrocco & Stewart, 2001 ). Women 
remain underrepresented in clinical trials, and publication of gender-related information 
remains inadequate, despite established guidelines for inclusion of women in clinical trials 
and reporting of gender differences in drug responses (Josephson, 1997; Birmingham, 
1997; Recruitment of women to clinical trials (editorial), 2001). 
Comparatively small numbers of women have been enrolled in clinical trials on which 
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treatment of coronary heart disease is based. Consequently, depending on patient gender, 
physicians may offer different treatment options, or they may generalize study results and 
apply identical treatment options without conclusive evidence of effectiveness. This bas a 
significant impact on patterns of practice in the treatment of CAD in the female population 
(Heston and Lewis, 1992). Confirmation of the effectiveness of coronary artery disease 
therapies in women might improve use of proven effective therapies in females. 
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2.3 GENDER BIAS IN CLINICAL PRACTICE 
During the 1980's and 1990's women's health issues have received a great deal of 
attention. This has increased awareness that some therapeutic options are not distn"buted 
equally among the sexes. Women are less likely to receive intensive management options 
at several junctures in health care delivery. 
Many controversies still exist regarding the outcome of myocardial infarction in women. 
This is probably due to lack of definitive post myocardial infarction studies done in 
women. Most current data is based on post-hoc analysis of small numbers of women 
enrolled in predominantly male clinical trials. Other data has been derived from 
administrative databases or retrospective chart reviews with their inherent methodological 
flaws. 
2.3.1 Intervention in Unstable Angina and Acute Myocardial Infarction 
The proportion of Canadian females admitted to hospital with AMI is increasing (Kannel 
& Thorn, 1990; Naylor & Chen, 1994). Canadian in-hospital revasculariza.tion rates are 
higher than they were 10- 15 years ago. This, combined with introduction of numerous 
other interventions, is responsible for improvement in post-myocardial infarct prognosis 
(Heidenreich & McClellan, 2001 ). Most experts agree that prognosis after myocardial 
infarction (MI) is worse in Canadian women (Tsuyuki, Koon, Ikuta et al, 1994; Naylor & 
Chen, 1994; Rouleau, Talajac, Sussex et al1996), but it remains uncertain whether this is 
related to age, severity of coronary artery disease or the presence of more active risk · 
factors. This may be partly due to sex-related differences in assessment and treatment 
(Jenkins, Flaker, Nolte, et al, 1994). 
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Improvements in survival followiilg AMI have been most dramatic in the past two 
decades, since adoption of treatments such as aspirin, thrombolytic~ anticoagulants and 
beta-blockers (Naylor & Chen, 1994; Rouleau et al, 1996). Standard intervention for 
patients with acute coronary syndromes (ACS) includes establishing patency of the infarct 
related artery and reducing the extent of myocardial ischemia and/or necrosis. 
Development of time-dependent treatments, such as thrombolytic agents for AMI, makes 
rapid assessment and intervention of the essence. Expeditious and universal use of 
reperfusion therapies is the goal of care for AMI patients with ST elevation on ECG. 
2.3.1.1 Emergency Management 
Little information is available regarding presentation, assessment and treatment of women 
with chest pain in emergency rooms. Studies examining gender bias in diagnostic and 
therapeutic approach to patients with new onset non-traumatic chest pain report 
contradictory findings. At least one report suggests that no gender bias exists in the 
evaluation and treatment of patients presenting to emergency departments with chest pain 
(Silbergleit & McNamara, 1995). The preponderance of evidence suggests that women 
and m,en with similar age, risk fuctor profiles, presenting complaints, and co-morbid 
illnesse~ are assessed and managed differently (Heston & Lewis, 1992; Lehman, Wehner, 
Lehman et al, 1996; Jackson, Anderson, Peacock, Va~ Carley and Wdson, 1996). 
Although not validated by other studie~ it has also been reported that patients who have a 
MI confirmed by electrocardiograph (ECG) or cardiac enzyme evidence, are probably 
treated with equal aggression regardless of gender (French, Williams, Hart et al, 1996). It 
has also been claimed that a large majority of patients presenting to emergency 
departments with acute myocardial infarction are properly diagnosed and admitted 
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regardless of sex (Karlson, Herlitz, Hartford and Hjalmarson, 1993). Others suggest that 
men are evaluated earlier (Heston & Lewis, 1992; Lehman et a1, 1996), treated more 
aggressively, and admitted more :frequently than women (Lee, Gregory, Weisberg et al, 
1987; Heston & Lewis, 1992; Lehman et al, 1996; Chandra, Ziegelstein, Rogers et al 
1998). Some studies have shown that MI is confirmed more often in men, than women 
(Karlson, 1993; Heston & Lewis, 1992; Silbergleit & MacN~ 1996), and that the 
difference in management is appropriate (Karlson et al, 1993). 
Emergency assessment and subsequent management play a vital role in patient outcome. 
The optimum benefit of intervention for acute coronary syndromes is achieved if treatment 
with thrombolytics, acetylsalacylic acid (ASA), beta-blockers, and angiotensin converting 
enzyme (ACE) inhibitors is initiated soon after onset of symptoms. However, delay in 
patient presentation, treatment, and under-utilization of these pharmacologic interventions 
(Goldberg, Gurwitz, Yarzebski et al, 1993; Barron, Bolby, Breen et al, 1998; Chandra et 
al, 1998) continue to be important problems with many contributing factors. 
2.3.1.2 Thrombolytics 
There is no evidence to suggest that coronary thrombosis evolves differently in males and 
females. There is considerable evidence that women, despite increased risk of bleeding, 
gain substantial benefit :from thrombolytic therapy (Becker, Terrin, Ross et al, 1994; 
White, Barbash, Modan et al, 1993) and that aggressive reperfusion therapy yields similar 
outcomes for men and women (Becker, 1995). Current guidelines of the American 
College of Cardiology (ACC) and the American Heart Association (AHA) recommend 
administration of thrombolytic therapy to all patients without contraindications, in whom 
AMI is suspected, regardless of age, sex, or race (Barron et al, 1998). However, women 
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and the elderly are more often considered ineligible for thrombolytics due to age, delayed 
presentation, oondiagnostic ECG's, and medical contraindications. Even when eligible, 
they are less often treated with thrombolytics (Maynard, Althouse, Cequeria et a1, 1991). 
While the Thrombolysis and Angioplasty in AMI (T AMI) trials demonstrated that 
controlling for clinical and angiographic differences produced similar mortality and 
thrombolytic utilization rates in men and women (Linco~  Ellis et a1, 1993), a 
similar approach in a retrospective cohort Japanese study of post MI patients showed that 
even after adjustment for baseline characteristics, women had higher mortality and lower 
thrombolytic utilization rates than men (Ma• Fulrui, Hira et a1, 2002). 
Delays before and after presentation contnoute to patient outcome. Over the last thirty 
years, public education has resulted in decreased delay between symptom onset and 
hospitalization. Patient delay in seeking attention and physician delay in referral continue 
to be major contnbuting :fu.ctors in Jate intervention for acute myocardial infarction. 
Delays occur even in patients with well-known risk factors and frequent medical contacts 
(Goldberg et a1, 1992) and are still more pronounced in women than men (Goldberg et a1, 
1992; Jenkins et a1, 1994; Clarke, Grey, Keating et a1, 1994; Karlson & Herlitz, 1996; 
Chandra et a1, 1998). 
Thrombolytics are more likely to be administered to patients presenting early after 
symptom onset. The greatest benefit is seen when thrombolytics are administered within 
six hours of symptom onset. In the Trandolopril Cardiac Evaluation (TRACE) study, 56 
%of patients presenting within two hours, and only twelve percent of those arriving more 
than twelve hours after symptom onset, were treated with thrombolytic therapy. Longer 
delay was associated with higher mortality (Ottesen, Kober, Jorgenson et a1, 1996). 
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Canadian physicians are reported to be significantly slower than their US counterparts in 
initiating thrombolytic therapy (Williams, 1997). Elderly and hypertensive patients are 
more likely to experience a delay in administration ofthrombolytics therapy (Goldberg et 
al, 1992; Barron et al, 1998). As women presenting with MI are typically older and have 
higher incidences of hypertension than their male counterparts, delay in initiation of 
thrombolytics therapy is more likely to be seen in women. This may expose Canadian 
women to a greater risk of death than United States (US) women following AMI. 
Reductions in time-to-treatment with thrombolysis have been achieved by Canadian 
physicians in recent years (Markel, 1997). 
It has been reported that, despite probable underutilization of most accepted post MI 
interventions, there appears to be no gender difference in the use ofthrombolytics 0facek, 
Handlin, Rosamond et al, 1995; French et al, 1996;). However, only 31 % of patients 
presenting with AMI in the US are considered eligible for thrombolytic therapy. Twenty 
four percent of patients are not treated despite being eligtble. Underutilization is 
particularly evident in the elderly, minorities, and women (Rathore, Berger, Weinfurt et at, 
2000). These groups are at the highest risk of in-hospital mortality (Clarke et a1, 1994; 
Chandra et a1, 1998; Rathore et a1, 2002). Among women who are eligible for 
thrombolytic therapy, 60 % are not treated and this cannot be explained by age or delayed 
presentation (Barron et a1, 1998). There has been at least one report of increasing 
numbers of women being treated with thrombolytics (Chandra et a1, 1998). 
2.3.1.3 ASA, Beta-blockers and ACE Inhibitors 
Therapies for secondary prevention ofMI, such as ASA, beta-blockers (Wegner, Speroff 
and Packard, 1993) and ACE inhibitors (Pffeffer, Braunwald, Moye et a1, 1992) appear to 
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have comparable efficacy in both men and women. Despite temporal trends for increased 
utilization of effective AMI therapies in North America (Pagley, Y arzebski, Goldberg et 
ai, 1993; Tsuyuki et ai, 1994; Martinez, Agusit, Amau et ai, 1998), Canadian patients are 
prescn"bed fewer medications than American patients following MI. In. the SAVE study, 
Canadian patients were significantly less likely than US patients to be prescn"bed cardiac 
medications, including beta-blockers, during hospitalization (Rouleau, Lemuel, Pfeffer et 
ai, 1993). Gan and colleagues demonstrated that, including only ideal candidates for 
receiving standard post-MI pharmacologic interventions ·eliminated gender differences in. 
administration ofbeta-blockers and ACE inhibitors (Gan, Beaver, Houck, MacLehose, 
Lawson and Chan, 2000). 
ASA 
The primary protective effects of aspirin have oot been demonstrated in females and the 
results of two primary prevention studies in men are conflicting (Steering Committee of 
the Physicians' Health Study Research Group, 1989; Peto, Grey, Collins et ai, 1988). The 
British male doctors study, which fiilled to demonstrate beneficial effects of aspirin in 
reducing coronary events (Peto et ai, 1988), bad a lower incidence of non-fu.tal MI than 
the United States trial, which demonstrated about a 30 % reduction in non-fatal MI 
(Steering Committee of the Physicians' Health Study Research Group, 1989). This 
supports positive finding of the US trial. However, the women nurses study noted a 
statistically significant reduction in risk of myocardial infarction in women who took low-
dose aspirin. Women who reported taking higher doses of aspirin were noted to have 
increased risk of hemorrhagic stroke (Manson, Stampfer, Colditz et ai, 1991). Some 
authorities have argued however, that because this was an observational study, it provides 
insufficient evidence for the cardio protective effect oflow-dose aspirin in women (Appel 
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and Bush, 1991 ). Rando~ data :from women's. studies are not available. The 
Women's Health Study, a randomized trial oflow-dose aspirin will provide more definitive 
data on primary prevention ofMI in women (Women's Health Study Research Group, 
1994). 
A review of randomized trials of antiplatelet therapy showed that aspirin reduces the odds 
of recurrent events following MI by as much as 34% (Antiplatelet Triatists Collaboration, 
1994; Tsuyuki et al, 1994). It is clear that following acute MI, regardless if sex significant 
risk reduction is achieved through aspirin use (Hennekens, 1999). It is recommended that 
all post MI patients receive aspirin unless contraindicated (Fallen et al, 1991; Ryan et al, 
1996). Evidence of aspirin's role in secondary prevention of coronary artery disease is 
based primarily on trials involving men, but additional evidence supports it has clear 
benefits in reducing risk of events in men and women (Yusut: Collins, MacMahon et al, 
1988; Antiplatelet Triatists' Collaboration, 1994). 
Some reports suggest that, during hospitalization post MI patients are prescribed aspirin 
equally regardless of gender (French et al, 1996; Wilkinson, Laji, Ranjadayalan, et al, 
1994). Following referral to an outpatient cardiologist, males are more :frequently 
prescn'bed ASA than females (Jaglal, Slaughter, Baigrie, Morgan, and Naylor, 1995). In 
the SAVE study, men received more ASA than women in the weeks preceding MI (Pfeffer 
et aJ, 1992). Lehman and coworkers reported that only 12% of women compared to 26 
% of men received ASA when presenting to the emergency room (ER) with chest pain 
(Lehman et al, 1996). Most reports indicate that during hospitalization (Chandra et al, 
1998; Rathore et al, 2000) and on discharge following AMI, significantly fewer women 
than men were prescn'bed aspirin (Clarke et al, 1994; Rathore et al, 2000). 
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Beta-Blockers 
The role of beta-blockers in post-infarction mortality reduction has been clearly 
established in clinical trials (Sial, Malone, Freeman et al, 1994; Yusuf et al, 1988, Martinez 
et al, 1998). It is generally accepted that, except when contraindications exist, beta-
blockers should be administered to all AMI patients (Fallen et al, 1991; Ryan et al; 1996) 
early in the post MI period and continued for two to three years thereafter (Hennekens, 
Albert, Godfried et al, 1996). However, following AMI, beta-blockers are underutilized in 
general (Sial et al, 1994; Rouleau et al, 1993) and withheld :from patients with diabetes 
and left ventricular dysfunction. Women are significantly less likely than men to receive 
beta-blockers during hospitalization (French et al, 1996; Cluutdra et al, 1998; Rathore et 
al, 2000) and on discharge (Jenkins et al, 1994; Willdnson et al, 1994; Sial et al, 1994, 
Clarke et al, 1994). Yet there are no randomized clinical trials specifically addressing the 
role ofbeta-blockers in females following AMI. 
ACE Inhibitors 
The role of ACE inhibitors in prevention of cardiac remodeling in AMI has been clearly 
established in clinical trials since the early 1990's (Pfeffer et al, 1992; French et al, 1996) 
and reinforced in the more recent Heart Outcomes Prevention Evaluation (HOPE) trial 
(Yusu:t: Sleight, Pogue et al, 2000). Improved survival following AMI has been shown to 
be associated with the use of ACE inlnbitors in the early post MI period (Pffeffer et al, 
1992). In addition, ACE inlnbitors have been shown to improve long-term survival in 
patients with left ventricular dysfunction. This is reflected in increased ACE inlnbitor 
prescription in secondary prevention after MI (Martinez et al, 1998). It has been 
recommended that all patients without oontraindications receive ACE inhibitors for at least 
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six weeks following MI (Hennekens et al, 1996). From the HOPE trial, it is evident that 
ACE inhibitors should be used in a broad spectrum of patients at risk of cardiac events 
(Sleight, 2002). However, data from randomized trials of ACE inhibitors in post-MI 
females are lacking. A recent Quebec study has reported that post MI patients, admitted to 
tertiary care settings, were significantly less likely to be prescn'bed ACE inhtoitors than 
those admitted to community hospitals (Beck, Lauzon, Eisenberg et al, 2000). 
2.3.1.4 Nitroglycerine, Heparin and Calcium Channel Blockers 
Some drugs previously touted for universal use in post-MI patients, have only limited use 
in special situations. Among these are nitroglycerine, heparin and calcium channel 
blockers. Nitrates are indicated in the treatment of angina but have no effect in 
progression of CAD and do not reduce morbidity or mortality post-MI (Anonymous, 
1996). Post-MI women have been shown to receive more nitrates than men (Clarke et al, 
1994). The effects of heparin on mortality are less certain than those of ASA, beta-
blockers and ACE inhtoitors (Heidenreich & McClellan, 2001 ). Heparin may be used as 
antithrom.botic therapy, in those not receiving thrombolytics, or as adjuvant to 
thrombolytic therapy. Treatment with heparin is less frequent in women (Chandra et al, 
1998). Calcium channel blockers have not been demonstrated to decrease mortality and 
have a role only when beta-blockers are contraindicated. Women have been shown to 
receive calcium channel blockers more often than men (Clarke et al, 1994). 
2.3.2 Noninvasive bchemicTesting (NDT) 
Early detection of CAD through effective use of noninvasive ischemic testing (NIIn has 
the potential to increase identification of patients at risk. During the Jast two decades 
several noninvasive diagnostic tests have become widely used in cardiac patients. These 
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tests are reported to have varying sensitivities and specificities, particu1arly in women, may 
influence their use in the female popu1ation. Noninvasive testing includes exercise stress 
electrocardiography (ECG), stress echocardiography, and nuclear cardiac imaging 
(thallium and sestamibi) tests. Overall the prognostic value of these tests in women is 
improving (Me~ Johnson, Kelsey et ~ 2001 ). 
Exercise stress ECG is the least reliable of noninvasive tests. This test has poor sensitivity 
and specificity and a higher rate of false positives in women than in men (Sketch, 
Mohiuddin, Lynch et ~ 1994). Stress echocardiography has bnpl:oved sensitivity and 
specificity over stress ECG and it provides additional information regarding cardiac 
function. However, it requires that the patient exercise and develop ischemia in order to 
identifY wall motion abnormalities. This may.result in false negatives if target exercise level 
is not reached. Image quality can also influence diagnostic value of the test. Stress echo 
is widely used and a recent publication suggests that it has value in identification of 
women with severe CAD (Merz et ~ 2001). 
Nuclear tests are favored in diagnosing CAD in women because they have superior 
sensitivity and specificity to stress tests and have been demonstrated to be effective in 
stratifYing women according to degree of risk (Hachmanovitch, Berman, Kiat et ~ 1995). 
These tests are useful in identifYing patients who require -more invasive testing. In 
addition, images can also be gated thereby separating attenuation defects from infarcts and 
allowing assessment ofheart function. Nuclear tests are also more beneficial in situations 
where patients are unable to exercise (Cequeria, 1995). Until recently, women were 
generally underrepresented in clinical trials of these diagnostic tests or the data was not 
analyzed by gender. In spite of this, there have been reports that the results were used in 
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the same manner in women as in men (Shaw, Miller, Romeis et aJ, 1994). 
An Ontario based observational study demonstrated rapid growth in the use of noninvasive 
cardiac diagnostic tests with the highest growth rate (157%) being exhibited in myocardial 
perfusion scans. A proportionately greater use of many procedures, most notably 
myocardial perfusion scans in women, contributed to increased utilization rates (Chan, 
Cox and Anderson, 1996). At least one other study has demonstrated increasing 
utilization of perfusion scans in women (Miller, Roger, Hodge et aJ, 2001). 
The optimal diagnostic strategy in eValuation of chest pain in women is sequential testing 
with referral of women with positive tests to the next level of evaluation (Shaw, 
Hachmanovitch and Redberg, 2000). Women are often deemed to have abnormal 
noninvasive test responses. This, combined with lower CAD prevalence reduces the 
ability of stress tests to accurately diagnose CAD in women. These issues may influence 
the physician's decision to refer women for noninvasive cardiac diagnostic tests (Mark, 
Shaw, DeLong et aJ, 1994). Myocardial perfusion scans appear to have similar prognostic 
accuracy regardless of gender (Marwick, Shaw, Lauer et aJ, 1999). 
Following presentation to emergency departments for acute chest pain, women are less 
likely than men to be admitted to hospital or to undergo stress tests in the first month 
following the event. Women, who are admitted to hospital, are as likely as men to undergo 
stress testing but less likely than men to undergo nuclear imaging or CA (Johnson et aJ, 
1996). 
Since :findings of noninvasive tests are often used in determining the need for more 
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invasive testing, the impact of patient referral for noninvasive testing has a significant 
impact on access to myocardial revascularization. 
2.3.3 Coronary Angiography and Revaseularization 
The American College of Cardiology and American Heart Association Task Force 
(ACC/ AHA TF) on Practice Guidelines (Committee on Management of Acute Myocardial 
Infarction) recommend that following MI~ patients who develop recurrent angina or 
evidence of ongoing ischemia or left ventricular dysfunction (L VD) should undergo CA 
(Ryan et a4 1996). Coronary angiography has been shown to be associated with lower 
mortality regardless of sex (Kostis, W:dson, O'Dowd, 1994). Although there are reports 
which indicate that coronary artery disease severity is similar in women and men following 
AMI (Jenkins et al, 1994), referral of females for CA has been influenced by studies that 
reported finding normal coronary flow in a high percentage of women referred for 
evaluation of chest pain (Fisher et al, 1982). 
It has been long demonstrated that grouping women on the basis of severity of anginal 
symptoms is effective in identifying those·with critical coronary artery stenosis (Welsh, 
Proudfit and Sheldon, 1975). After adjustment for age and thallium results, Lauer found 
that women were referred for coronary angiogram as :frequently as men (Lauer, Pashkow, 
Snadel et al, 1996). Both Hachma.novitch and Duca found that controlling for severity of 
abnormality on cardiac perfusion scans eliminated the difference in referral rate for cardiac 
catheterization and :frequency of cardiac events between men and women (Hachmanovitch 
et al, 1995; Due~ Tra~ Herman et al, 1996). 
Regardless of country and type ofhealthcare system (Jaglal, Goel, Naylor et ai, 1995), the 
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majority of studies report that women are referred for CA significantly less often than men 
(MeG~ et ~ 1994) even when age~ functional disability~ and comorbid illness are 
accounted for (Steingart et al1991; Anyan and Epstein, 1991; Pfeffer et ~ 1992; 
Maynar~ Litwin, Martinet~ 1992; Kee, Gaffuey, Curry et ~ 1993; Johnson et ~ 1996) 
or when CA is deemed necessary by objective assessment of need (Garg, Landrum, 
Norman~ et ~ 2002). 
Utilization of CAin patients with chest pain and no previous history of CAD has not been 
the subject of many studies. This group comprises a 1arge segment of the population 
referred for invasive diagnosis. Studies refute the presence of referral bias in this patient 
population. One such study reveals that in all decades of life~ a greater proportion of 
women than men were referred for CA. Significantly greater numbers of women had 
normal coronary arteries and the extent of disease and L VD was comparable in both sexes 
also refuting the claim of later referral in women (V aitkus, 1995) 
In contrast, a Canadian study suggests bias may be operating at all levels of the referral 
chain. This study found that, even when angina severity was accounted for, females with 
newly suspected CAD were significantly less likely than men to have had referrals for 
noninvasive diagnostic testing, or for CA when noninvasive testing was positive (Jaglal et 
~ 1995). In similar groups of patients in other studies, it has been reported that men were 
significantly more likely than women to be referred for CA following abnormal cardiac 
noninvasive perfusion tests (Tobin, Wassertheil, Wexler et ~ 1987; Shaw, Miller, Romeis 
et ~ 1994; Miller et ~ 2001). 
It has been suggested that once women present with definite diagnosis of AMI or have 
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undergone invasive diagnosis and are shown to be as sick as men they are treated with 
equal aggressiveness (Healey; 1991; Maynard et a1, 1992; Demirovic, BJackbum, 
McGovern et a1, 1995). In these patients, CA is generally used to determine disease 
severity and help select the best treatment option Gender difference in referral for CA 
should not be evident in this population (Bell, 1996). 
There are many reports of similar rates of CAin post MI patients. A study by K.rumholtz 
and coworkers found, that by controlling for age, they were able to eliminate differential 
referral rates for CA and PTCA and reduce differential referral rates for CABO to 
borderline statistical significance (Krumholtz, Doug]as and Lauer, 1992). A study by 
Mark and others revealed that after accounting for lower pre-test probability of coronary 
disease and lower rate of positive exercise tests, gender was not related to referral for 
cardiac catheterization (Market a1, 1994). A recent publication by Rathore finds that 
risk-standardization of rates for cardiac catheterization reduced most of the sex differences 
in procedure utilization in elderly post MI patients. Rates of use were similar between 
men and women with strong indications, whereas rates were slightly lower in women with 
equivocal indications for cardiac catheterization (Rathore, Wang, Radford et a1, 2002). 
The SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK 
(SHOCK) trial, which included patients from five Canadian centres, revealed that, after 
adjusting for demographics and treatment approaches, women were more likely to 
undergo CA than men (Wong, Sleeper, Monrad et al, 2001). 
PTCA has demonstrated improved survival in high-risk post myocardial infarction patients 
(Vacek et al, 1995) and is now the procedure of choice in treating AMI (Azar, Waters, 
McKay et a1, 2000). Procedural success rate is similar in women and men (Azar et a1, 
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2000; Peterson, Lansky, Kramer et al, 2001). Higher risk of :female mortality and post 
procedural complications have been seen (Wegner et al, 1993; kzar et al, 2000; Peterson 
et al, 2001) in several studies, but more recent data suggest similar short-tet'ID, medium-
term, and long-term outcome for both sexes, after controlling for demographic and clinical 
variables and body surface area (BSA) (Philippides and Jacobs, 1995; Jacobs, Kelsey, 
Brooks et ai, 1998; kzar et al, 2000; Peterson et al, 2001). In one study of very ear]y 
revascularization with percutaneous intervention (PCI), women were shown to have better 
long-term outcome than men (Mueller, Neumann, Roskamm et al, 2002). 
Two studies found that women were as like]y as men to undergo PTCA but less likely to 
have CABO (Bell, Berger, HoJmes et al, 1995; Bergelson and Tommaso, 1996). While 
the difference in revascularization strategy was unexplained in one study (Bergelson and 
Tommaso, 1996) clinical differences, making women less desirable surgical candidates, 
were evident in the other (Bell et al, 1995). Another study noted that over time a 
significant increase' was seen in the number ofPTCA's performed in women and a 
significant decrease was seen in the number of CABO's performed in men (Roeters van 
Lennep et al, 2000). 
Coronary artery bypass grafting is effective in reducing angina and prolonging life in 
patients with severe disease. Throughout the last decade there has been progressive 
increase in the number of women having CABO (Abramov, Tamariz, Sever et al, 2000). 
Women have consistent]y been reported to have higher perioperative complications than 
men, including mortality (Wegner et al, 1993; Tan, van der Meer, de Kam et al, 1999; 
Abramov et al, 2000). It has been demonstrated that less favorable clinical outcome is 
related, not to gender, but to unequal distribution of risk factors (Tan et al, 1999; 
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Abramov et ~ 2000). A recent study reports that, while women were more likely to 
require inotropic support and to have longer hospital sta~ controlling for differences in 
risk fu.ctors eliminated the sex difference in death, perioperative MI, and cerebrovascular 
accident (CVA) (Aldea, Gaudiani, Shapira et ~ 1999). Long-term mortality for women 
who undergo CABG has been demonstrated to be similar to that of men (Pbilippides and 
Jaco~ 1995). A Canadian study of ahnost 5,000 CABG patients, followed for up to nine 
years, showed actuarial survival at sixty months to be greater in women than men, when 
adjustment occurred for other risk variables (Abramov et ~ 2000). The authors wondered 
if this was related to later disease onset and greater longevity in women. Similar results 
were seen in the Bypass AngiopJasty Revascularization Investigation (BARI) study but 
this was a selected group of patients amenable to both CABG and PTCA (Jacobs et ~ 
1998). Graft patency at one year has been shown to be similar in men and women 
undergoing CABG (Tanet ~ 1999). 
Several studies have found evidence that North American women have less access to 
revascularization after CA than men (Pffeffer et ~ 1992; Naylor et ~ 1993; Jaglal et ~ 
1994; Schulman, Berlin, Harless et ~ 1999; Chandra et ~ 1998) .. It has been claimed that 
when the survival benefit is low, women are more often treated medically while men are 
referred for surgical intervention (Tobin et ~ 1987; Bickell, Pieper, Lee et ~ 1992) and 
that this reflects appropriate treatment (Bickell et ~ 1992). Without outcome data it is 
difficult to determine whether this is true. In many studies, revascularimtion rates have 
been reported to be similar in men and women with known or suspected CAD (Tobin et 
~ 1987; Chriboga, Yarzebski, Goldberg et ~ 1993; Johnson et ~ 1996; Bell, Berger, 
Hohnes et ~ 1995; Bergelson and Tommaso, 1996; Roeters van Lennep, Zwinderman, 
Roeters van Lennep et ~ 2000; Miller et ~ 2001). Some have suggested that gender bias 
27 
in referral to revascuJarization is not evident when disease severity is considered (Tobin et 
al, 1987; Bell, Berger, Hohnes et al, 1995; Bergelson and Tommaso 1996; Roeters van 
Lennep et al, 2000). An Alberta study of revascularization after C~ has demonstrated that 
adjusting analysis for clinical variables, especially the extent of coronary disease, can 
eliminate the differences in revascularization rates between women and men, regardless of 
revascularization strategy (Ghali, Faris, Galbright et al, 2002). Likewise in the SHOCK 
study, where, once adjustments were made for patient characteristics, no gender bias was 
seen in selection of patients for revascu1ar;ization (Wong et al, 2001). 
2.3.4 Appropriateness ofRevaseularization 
Rates of coronary revascu1arization vary widely between and within countries. A 1997 
report indicates that, in 1992, the rate of combined CABG and PTCA varied from 515 per 
million in the United Kingdom to 2676 per million in the United States (Meijler, Rigter, 
Bernstein, et al, 1997). Two Canadian studies show that rates ofCABG vary by province 
(MeG~ Naylor, Anderson, et al, 1994; Anderson, Pinfold, Hux, et al, 1997). This 
makes it somewhat difficult to define the optimal rate at which CABG should be utilized. 
Consequently, during the last ten years attention has been focused on devising 
appropriateness scores for revascuJarization decisions. This is of particular importance 
when specialized care is regionalized, potentially intluencing access to procedures such as 
coronary revascularization. Also, when limited resources are available, these ratings may 
help to ensure that overuse and underuse of coronary revascWarization is minimized. 
The RAND/UCLA (Research and National Defense/University of California at Los 
Angeles) appropriateness method, which requires a panel of experts to review and rate the 
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appropriateness of indications for a medical procedure in two rounds, bas been applied to 
a variety of medical procedures (Rigter, Meijler, McDonnell, et al, 1991). While this 
method received some criticism of its ability to identify overuse, it has been shown to have 
highly reproducible results in detecting underuse of revascula.rization (Shekelle, Kahan, 
Bernstein et al, 1998). This method bas been used as the basis for developing Canadian 
appropriateness criteria for CA and CABO (McGlynn et al, 1994). 
It has been demonstrated that Canadian physicians in two provinces make similar decisions 
regarding appropriate use of CABO (Anderson et al, 1997). Several studies have found 
that rates of inappropriate revascularization, especially inappropriate CABO, are as low as 
two to five percent in Canadian provinces and generally less than ten percent in the United 
States and Europe (McGlynn et al, 1993; Meijler et al, 1997; Bernstein, Brorsson, Aberg 
et al, 1999). 
It should be expected that patients receiving revascularization, in whom it is considered 
appropriate, would have better outcomes than those in whom it is considered 
inappropriate (Rigter et al, 1997; Hemingway, Crook, Dawson et al, 2001). Substantial 
underuse of coronary revascula.rization in patients considered appropriate has been 
identified and found to be associated with poor clinical outcomes. Patients who received 
medical management, despite being classified as appropriate for CABO, were more likely 
to have angina, MI, or to have died at follow up than those who received CABO. This 
demonstrates the clinical validity of appropriateness ratings (Hemingway, Crook, Feder, et 
al, 2001 ). There are no published data addressing gender and appropriateness of coronary 
revascular:ization. 
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The literature includes many explanations for lower rates of CA in. women including 
perception of more severe CAD in. :men, inaccurate noninvasive testing, poor outcome in. 
women and referral at a later stage in. the disease process. It has also been suggested that 
differences in. treatment approach could be explained by gender bias (Johnson et al, 1996). 
Although earlier publications claimed lower rates ofCA and revascu1arization in. women, 
later studies have demonstrated that gender becomes less important when clinical 
differences, disease severity, and appropriateness of procedures are considered (Azar et al, 
2000; Rathore et al, 2002;Ghali et al, 2002). 
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3 Gender Bias in Newfoundland and Labrador 
3.1 GENDER AND CLINICAL OUTCOMES, TREATMENT AND 
MORTALITY FOLLOWING ACUTE MYOCARDIAL INRFARCTION 
(NLMI STUDY) 
3.1.1 Context 
Coronary artery disease is the leading cause of morbidity and mortality in Canada. As the 
population ages, the severity of this problem will become more evident, particularly in 
women who live longer than men. As female mortality due to cardiovascular disease is 
higher in NL than other Canadian province~ this province will be disproportionately 
affected by this problem. 
Gender bias in delivery of medical care to cardiac patients is controversial Little is 
published about the association between gender and delivery of cardiac care in Canadian 
institutions. The province ofNL has a high prevalence of cardiovascular disease but there 
is little information regarding gender bias in treatment, or impact on outcome, in 
cardiovascular patients in this province. 
3.1.2 Objective 
To determine if gender bias exists in the treatment of AMI in Newfoundland and 
Labrador. 
3.1.3 Hypothesis 
Female sex is associated with less aggressive treatment and assessment and poorer 
outcome following myocardial infarction in Newfoundland and Labrador. 
3.1.4 Methods 
These data were originally collected in the context of the (Signal Averaging ECG) SAGES 
study and subsequently stratified by sex and reanalyzed for the purpose of this study. The 
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SAGES study was undertaken to determine if it was possible~ using signal averaging 
electrocardiography (SAECG),. to predict which patients were at the greatest risk of 
developing ventricular arrhythmias following MI. 
Between May 24, 1990 and December 31, 1992,698 consecutive patients presenting to 
two tertiary referral centres in St. John's, NL with an AMI were documented in a 
prospective fashion. One of these hospitals contained the only provincial fucility for 
cardiac catheterization and cardiac surgery. Patients were identified by a daily review of 
admissions to the coronary care unit, intensive care unit, and the cardiology ward. In 
additio~ all patients undergoing bypass surgery were reviewed to identify perioperative 
myocardial infarction. All deaths in the emergency department were also reviewed and all 
patients meeting the study criteria were included in the study. Exclusion criteria were 
limited to patient or physician refusal, permanent pacemaker dependant, malignant 
neoplasm or other criteria making the patient unsuitable for study. 
Prior to October 1991, patients greater than 75 years of age were excluded. Due to slow 
study enrollment it was subsequently decided to include subjects regardless of age. 
Data were collected by trained research nurses and verified by a cardiologist. All data 
were collected prospectively using uniform procedures for data collection and entry which 
were outlined in a protocol and reinforced with training sessions before the start of patient 
enrollment and at annual meetings thereafter. Information was obtained from chart 
review, patient and family interviews and physician interviews. 
Demographic variables included age, gender, :family history, diabetes (DM), 
hypercholesterolemia, hypertension and smoking. Cardiac history included previous 
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angina, MI, congestive heart failure (CHF), angiographic evidence of CAD, CABO, 
PTC~ aortic (A VR) or mitral (MVR) valve replacement or other relevant conditions. It 
. 
was also determined whether the patient was transferred from another institution. 
Acute myocardial infurction was defined as having at least two of the following: 1) chest 
pain lasting at least 20 minutes, 2) new Q wave of at least 0.04 seconds in at least two 
contiguous leads on 12-lead ECG, or 3) creatinine kinase (CK) 2:: 1.5 times the upper limit 
of normal or creatinine kinase myocardial band (CK-MB) positive when CK was greater 
than the upper limit of normal. Probable acute myocardial infurction was defined as 
someone who died within four hours after having at least twenty minutes of chest pain and 
continuous 8T segment elevation in at least two contiguous leads on a 12-lead ECG, but 
who did not meet the above criteria for an acute myocardial infurction. Definite and 
probable myocardial infurctions were considered together in this data analysis. 
Killip class was assigned to each patient on the basis of severity of signs of heart failure at 
first assessment. Killip 1 is defined as absence of rales in the lung fields and absence of an 
83 heart sound; Killip 2 is defined as rales in~ 50% of the lung :fields and presence of an 
83 or jugular venous distention; Killip 3 is defined as rales in > 50010 of the lung :fields; and 
Killip 4 is defined as presence of pulmonary edema with hypotension. For the purposes of 
this study, Killip class of at least 2 was defined as CHF. 
Complications ofMI, including recurrent angina (> 48 hours after the qualifYing infurct), 
recurrent angina with ECG changes (> 1mm ST segment shift, re1ative to the painfree ECG 
that resolves within 30 minutes of the pain termination), recurrent MI (post index MI) and 
cardiac arrest were documented. Additionally, electrical complications including Mobitz 
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II second degree atrioventricular (A V) block, third degree A V block, Left bundle branch 
block, Right bundle branch block, left anterior or posterior hemiblock, ventricular 
tachycardia (VT) and ventricular fibri.Uation (VF) were documented. Interventions used to 
treat acute myocardial infarction were assessed. These included electrical interventions 
(chemical and electrical cardioversion, defibrillation and pacemakers), coronary 
angiograms, revascula.riution (CABO and PTCA), other surgical interventions (valve 
replacements) and pharmacological interventions (thrombolysis, IV heparin, IV 
nitroglycerine, IV beta-blockers). All other pharmacological treatments administered 
during hospitalization were tabulated. There were no predefined criteria for receiving CA, 
CABO or PTCA. 
Patients who survived for five days were asked to participate in more in-depth evaluation, 
including SAECG, twenty-four"hour Holter monitoring and left ventricular ejection 
fraction before hospital discharge. Additionally they were invited to participate in a thirty-
six-months follow-up program. 
During 36 months of follow-up, patients visited the clinic or were contacted by telephone 
at six, twelve, 24, and 36 months following the index MI. During clinic visits, patients 
again underwent SAECG. Using the Goldman scale (Goldman, Cook, Mitchell, Flately, 
Sherman and Cohn, 1982), a specific activity scale, data was collected regarding current 
functional c1ass. The Goldman scale uses external objective standards based on patient 
interview as a reference by which to measure current disability. With the Goldman scale, 
higher scores indicate greater functional impairment. Goldman functional status c1ass of at 
least two indicates some activity limitation. Patients were also interviewed to determine 
the cause of activity limitation. Details of the Goldman scale are outlined in Appendix 1. 
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Information was a1so collected regarding complications (angina, unstable angina, MI, loss 
of consciousness, VT and VF) and procedures (CA, PTCA, CABO, aortic valve 
replacement mitral valve replacement, permanent pacemaker, cardioversion, defibrillation 
and electrophysiologic studies (EPS), current medications, exercise routine, smoking 
status and vital status. Details concerning death were ascertained and classified by an 
independent mortality committee according to a predefined classification. Death was first 
classified as cardiovascular or non-cardiovascular. Cardiovascular death was then sub-
classified as 1) recurrent MI, 2) low output, 3) arrhythmic, 4) procedural, and 5) other 
cardiovascular (cerebrovascular accident (CVA), aneurysm, pulmonary emboli, cardiac 
rupture, peripheral, or renovascular disease). 
By December 1995 all patients had at least 36 months offollow:.up. 
3.1.5 Statistical Analysis 
The study population was stratified by gender. Differences between males and females 
were evaluated for statistical significance by use of the Chi-square statistic for categorical , 
variables and by Student's t-test for continuous variables. In multivariate analysis, logisitic 
regression models were developed to estimate association between sex and post-MI 
treatmen~ after adjusting for possible confounding variables. In these models, the 
treatments were the dependent variables and sex was among the independent variables. In 
addition to sex, the models included the following possible confounding variables: age, 
diabetes, hypertension, previous MI, previous angina, and previous CHF. Cox regression 
analysis was used to identifY independent predictors of hospital readmission and death 
following the initial MI. Gender, age, diabetes, hypertension, CHF, previous MI, previous 
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angina, recurrent MI in hospital, recurrent angina in hospital, CHF in hospital, 
revascularization following MI and treatment with ASA, ACE inhibitors, beta-blockers 
arid calcium channel blockers were entered into the model Cumulative survival curves for 
time to death and time to hospitali~tion following MI were constructed using the Kaplan-
Meier method. A p value ofless than 0.05 was considered to indicate statistical 
significance fur all comparisons in the study. The SPSSX program was used fur all 
statistical analysis .. 
3.1.6 Results 
3.1.6.1 Demographics 
The study population was comprised of214 (30.7 %) females and 484 (69.3 %) males. 
Approximately equal percentages of men and women (25.2% versus 24.3 %respectfully) 
were transferred from another facility. Women were significantly older (65 ± 11 years; p = 
0.005) than men (60 ± 12 years) on presentation. As documented in Table 1, comparison 
of patient characteristics showed that, although fewer women smoked, they were more 
commonly hypertensive or diabetic. Incidence of previous angina, previous MI or CHF 
was not significantly different between women and men. 
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Table 1. Gender and Risk Factors for Ml 
Risk Factor Male N (%) FemaleN (%) Pvalue 
Family History IHD 234 (48.8) H2 (54.1) NS 
Hypertension 117 (36.6) 119 (55.6) <0.001 
Diabetes H2 (23.1) 72 (34) 0.003 
Previous Angina 210 (43.8) 104 (48.6) NS 
.PreviouMI 139 (28.8) 63 (29.4) NS 
CHF 50 (10.4) 33 (15.6) NS 
Smokers 420 (87.5) 106 (51.2) < 0.001 
Significantly more men than and women had previous angiographic evidence of coronary 
artery disease, defined as at least 70 % occlusion of at least one coronary vessel. 
Likewise, significantly more men than women 1uid previous surgical coronary 
revascu]arization (see Table 2). 
Table z. Gender and Invasive Interventions Prior to Ml 
Procedure MaleN(%) FemaleN (%) Pvalue 
CADonCA 117 (24.5) 17 (36) 0.03 
CABG 51 (10.6) 4.2 (9) 0.006 
fiCA 17 (3.5) 6 (2.8) NS 
From Table 3, it is evident that significantly more men had a Q-wave myocardial 
infarction. Wtthin the Q-wave infarct group, it was found that a statistically significant 
number of men had suffered an anterior wall MI. There was no gender difference in 
occurrence of inferior, .lateral, or posterior wall infarcts. However, after controlling for 
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infarct type, it was found that women with Q-wave infarcts were significantly more likely 
than men with Q-wave infarcts to develop recurrent angina and recurrent MI's. 
Regardless of infarct type, women were more likely to develop moderate to severe CHF, 
defined as Killip Class 3 or higher. As expected, clinical and laboratory characteristics of 
index myocardial infarction were similar in both groups. 
Table 3. Gender and Description of Current AMI 
MI Charaeteristie MaBeN(%) FemaleN(%) Pvalue 
Q-waveMI 262 (54.1) 97 (45.3) 0.03 
AnteriorMI 107 (22.1) 31 (14.5) 0.02 
Non-Q-wave MI 222 (45.9) 117 (54.7) 0.03 
Enzyme rise 480 (99.2) 212 (99.1) NS 
Chest pain 469 (96.9) 207 (96.7) NS 
During AMI admission, significantly more women bad recurrent angina and recurrent MI. 
There was no gender difference in the incidence of CHF when defined as Killip Class of 2: 
2. However, women were significantly more likely to suffer from more severe CHF, 
defined as Killip Class 2: 3. Female mortality was also significantly higher than male 
mortality during the post MI admission (see Table 4). 
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Table 4. Gender and Post-Ml Complications in Hospital 
Complication MaBeN(%) FemaleN(%) 
Recurrent Angina 137 (28.9) 78 (37.5) 
Recurrent Angina with 42 (8.8) 28 (13.3) 
ECGebanges 
Reeurrent MI 19 (3.9) 20 (9.4) 
Killip Class ;:: l 215 (44.4) 104 (48.6) 
KiUip Class ;:: 3 60 (12.4) 46 (21.6) 
Death 36 (7.4) 27 (12.6) 
3.6.1.2 Treatment for Current Myocardial Infarction 
3.6.1.2.1 Noninvasive Treatment 
:r value 
0.03 
NS 
0.04 
NS 
0.002 
0.03 
As shown in Table 5, comparable use of pharmacologic interventions was seen in men and 
women during post-MI hospitalimtion. However, beta-blockers and ACE-inlul>itors were 
underutilized in both groups. Despite evidence of CHF (Ki1lip Class ~ 2) in 44.4 % of 
males and 48.6% of females, less than 25 %in each group received ACE-inlul>itors 
following MI. Beta-blockers were administered to only 29 % of males and 27 % of 
females. Further analysis showed that there was no significant difference in the beta-
blocker prescription rate between diabetics and non-diabetics or patients with and without 
historic CHF. Chi-square analysis of beta-blocker prescription rates in patients suffering 
poSt-MI CHF, defined as K.illip Class 2 or higher, however revealed that only 28 % of 
those receiving beta-blockers had Killip Class~ 2 (p < 0.01). A significant gender 
difference was seen in heparin administration. Men were significantly more likely than 
women to receive IV heparin follo~ MI. 
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Table 5. Gender and Noninvasive Post MI Treatment 
Treatment MaleN(%) FemaleN(%) :r value 
Thrombolyties 173 (35.9) 60 (28.3) NS 
IV Heparin 322 (67.2) 122 (57.8) 0.02 
IV Nitroglycerine 339 (70.5) 141 (66.8) NS 
ASA 284 (79.8) 104 (75.4) NS 
Beta-blockers 104 (29.2) 37 (26.8) NS 
ACE inhibitors 78 (21.9) 33 (23.9) NS 
Caleium channel 127 (35.7) 62 (44.9) NS 
blockers 
Tables 6 to 10 include results oflogistic regression analysis on relationship of 
demographic and clinical characteristics to prescription of standard post-MI medical 
treatments. Each model included the baseline variables sex, age ~ 65 years, diabetes, 
hypertension, previous MI, previous angina and CHF. Multiple logisitic regression (MLR) 
analysis revealed that age~ 65 years (OR 0.3; 95% CI 0.2 to 0.5; p < 0.001) and diabetes 
(OR 0.5; 95% CI 0.3 to 0.8; p = 0.003) were negative predictors of receiving IV 
thrombolytics; age~ 65 years (OR 0.6; 95% CI 0.4 to 0.8; p < 0.001) was the only 
predictor of receiving IV nitroglycerine; age~ 65 years (OR 0.5; 95% CI 0.3 to 0.7; p < 
0.001) and a history ofCHF (OR 0.3; 95% CI 0.2 to 0.6; p < 0.001) were negative 
predictors of receiving IV heparin; a history ofhypertension (OR 2.3; 95% CI 1.5 to 3.7; 
p < 0.001) or CHF (OR3.6; 95% CI 1.7 to 7.4; p < 0.001) were associated with receiving 
ACE-inhibitors, while a history of previous angina (OR 1.8; 95% CI 1.0 to 3.1; p = 0.03) 
was a positive predictor and CHF (OR 0.4; 95% CI to 0.2 to 0.9; p = 0.03) was a 
negative predictor for being prescn"bed ASA None of the demographic or clinical 
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variables included in the regression models were found to be associated with prescription 
ofbeta-blockers or calcium channel blockers (results not shown). Gender did not prove to 
be an independent predictor for receiving any pbarmaoologic intervention following 
myocardial infarction However, younger age ($ 65 years) was associated with receiving 
more aggressive acute medical interventions (thrombolytics, IV nitroglycerine and IV 
heparin). 
Table 6. Logisitic Regression Analysis of demographic and clinical characteristics 
predicting administration of W Thrombolytics post-MI. 
Variable Odds Ratio 
Sex (male) 0.9 
Age:::,65 0.3 
DM 0.5 
* DM indicates Diabetes Mellitus. 
95% CI 
0.6- 1.4 
0.2-0.5 
0.3-0.8 
Pvalue 
NS 
<0.001 
0.003 
Table 7. Logisitic Regression Analysis of demographic and clinical characteristicS 
predicting administration of!V Nitroglycerine post-Ml 
Variable 
Sex (male) 
Age;:. 65 
Odds Ratio 
1.1 
0.6 
95%CI 
0.7- 1.6 
0.4-0.8 
Pvalue 
NS 
<0.001 
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Table 8. Logisitic Regression Analysis of demographic and clinical characteristics 
predicting administration of IV Heparin post-Ml 
Variable 
Sex (male) 
Age~5 
CHF 
Odds :Ratio 
1.3 
0.5 
0.3 
* CHF indicates Congestive :Heart Failure 
95% CI 
0.9- 1.9 
0.3-0.7 
0.2-0.6 
f' value 
NS 
< 0.001 
< 0.001 
Table 9. Logisitic Regression Analysis of demographic and clinical characteristics 
predicting administration of Angiotensin Converting Enzyme (ACE) Inhibitors post-MI. 
Variable Odds :Ratio 95% CI f' value 
Sex(male) 1.1 0.6-1.8 NS 
Hypertension 2.3 1.5-3.7 < 0.001 
CHF 3.6 1.7-7.4 < 0.001 
* CHF indicates Congestive Heart Failure. 
Table 10. Logisitic Regression Analysis of demographic and clinical characteristics 
predicting administration of ASA (Acetylsalacylic acid) post-Ml 
Variable Odds :Ratio 95%CI f'value 
Sex(male) 1.2 0.7- 1.9 NS 
C.HF 0.4 0.2-0.9 0.03 
Angina .History 1.8 1.0- 3.1 0.03 
* CHF indicates Congestive Heart Failure. 
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3.1.6.2.2 Invasive Treatment 
Significantly more men underwent coronary angiography during post-MI hospital 
admission. When CABO and PTCA were considered separately, there appeared to be no 
gender difference in invasive intervention for myocardial revascularization. However, 
when they were combined, it was found that a significantly greater number of males were 
revascuJarized during the post-MI period (see Table 11 ). Seven males and two females 
underwent both CABO and PTCA following MI. Since these were considered as one 
revascularization, this explains the difference in numbers of CABO and PTCA when 
analyzed separately versus combined. 
Table 11. Gender and Invasive Post Ml Treatment 
Intervention MaleN(%) FemaleN(%) Pvalue 
CA 201 (41.9) 66 (31) 0.007 
CABG 51 (11.8) 17 (7.9) NS 
PTCA 43 (8.9) 11 (5.2) NS 
Revueularization 93 (19.3) 26 (12.2) 0.02 
In a model including only baseline characteristics (sex, age > 65 years, CHF, diabetes, 
hypertension, previous MI and previous angina) multiple logistic regression analysis 
revealed that age ~ 65 years, CHF and previous MI were negative predictors, whereas a 
history of angina was a positive predictor of receiving CA following MI. Male sex (OR 
1.4; 95% CI 1.0 to 2J; p = 0.049) was of borderline significance in predicting CA (Table 
12). 
Table 12 demonstrates that adding post-MI complications ofCHF (Killip Class 2 or 
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greater), recurrent MI and recurrent angina to the regression model increased the 
significance of male sex as apredictorofCA (OR 1.8; 95% CI 1.2 to 2.7; p = 0.00). Men 
were 80 % more likely than women to have CAin the immediate post-MI period. Age 2: 
65 years (OR 0.3; 95% CI 0.2 to 0.5; p < 0.001), CHF (OR 0.3; 95% CI 0.2 to 0.7; p = 
0.00) and previous MI (OR 0.6; 95% CI 0.4 to 0.9; p = 0.02) continued to be independent 
negative predictors for CA while a history of angina (OR 2.1; 95% CI 1.4 to 3.2; p < 
0.001) and recurrent angina following MI (OR 5.5; 95% CI 3.7 to 8.4; p < 0.001) were 
strong positive predictors for CA Recurrent MI and CHF following MI were not 
predictive ofCA in the post-MI period. 
Table 12. Two Separate MLR Models to Predict CAfollowing MI 
Baseline characteristics predictive of CA 
Variable Odds Ratio 95%CI Pvalue 
Sex(male) 1.4 1.0-2.1 0.05 
Age?!,_65 0.3 0.2-0.5 <0.001 
CHF 0.3 0.2-0.7 0.00 
Angina History 2.1 1.4-3.2 <0.001 
PreviousMI 0.6 0.4- LO 0.03 
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Table 12 (emit). Two Separate MLR Models to Predict CAfoUowing Ml 
Baseline characteristics and Post-MI complications predictive of CA 
Variable Odds Ratio 9S%CI 
Sex (male) 1.8 1.2- 2.7 
Age~65 0.3 0.2-0.5 
CHF 0.3 0.3-0.7 
Angina History 2.1 1.4-3.2 
Previous Ml 0.6 0.4-0.9 
Recurrent Angina 5.5 3.4-8.4 
* CHF indicates Congestive Heart Failme; MI indicates Myocardial Infarction. 
.P value 
0.005 
< 0.001 
0.01 
< 0.001 
0.02 
< 0.001 . 
In a model including only baseline characteristics (age 2::. 65 years, sex, diabetes, 
· hypertension, CHF, previous MI and previous angina), logistic regression analysis revealed 
that male sex (OR 1.8; 95% CI 1.0 to 3.0; p = 0.02) and previous angina were strong 
positive predictors, whereas CHF was a strong negative predictor for revascularization 
(see Table 13). Men were 80 % more likely than women to be revascu1arized during the 
immediate post-MI period. Addition ofpost-MI complications of recurrent angina, 
recurrent MI and CHF to the MLR model increased the predictive value of male sex (OR 
2.3; 95% CI 1.3 to 3.9; p= 0.03). Angina history continued to be an independent predictor 
and recurrent angina emerged as a strong positive predictor for revascularization. 
Historic CHF continued to be a negative predictor for revascularization during the post-
MI period. Recurrent MI and CHF following MI were not predictive of revascularization 
in the post-MI period. 
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Table 13. Two separate MLR Models to predict revascularization folluwing Ml 
Baseline characteristics predictive of revascularization 
Variable Odds Ratio 95%CI Pvalue 
Sex (Male) 1.8 1.1-3.0 0.02 
CHF 0.4 0.2-0.9 0.02 
Angina History 3.1 1.9-4.9 < 0.001 
Baseline Characteristics and Post-MI complications predictive o[revascularization 
Variable Odds Ratio 95%CI Pvalue 
Sex (Male) 2.2 1.3-3.8 0.00 
CHF 0.2 0.1- 0.7 0.01 
Angina History 3.0 1.7-5.0 < 0.001 
Recurrent Angina 7.0 4.3-11.0 <0.001 
• CHF indicates Congestive Heart Failure; MI indicates Myocardial Infarction. 
3.1.6.3 Clinical Picture During Follow-up 
Table 14 demonstrates that, evidenced by Goldman scores of at least two, women 
consistently had significantly poorer functional capacity than men throughout thirty-six 
months of follow-up. Except for the category other, it was not possible to isolate one 
consistent causal fuctor in activity limitation. Other was a non-specific category and · 
included patient fear, family fear, and physical impediments such as arthritis and previous 
hip injuries. The percentage of men reporting angina as the cause oflimitatio~ remained 
relatively stable (21% at 6 months versus 27% at 36 months). The percentage of women 
attributing limitation to angina gradually increased (22 % at 6 months versus 37 % at 36 
months) throughout the study, becoming statistically significant at 36 months post-MI (see 
Table 15). MLRanalysis revealed that age::; 65 (OR 0.4; 95% CI 0.3 to 0.7; p = 0.001) 
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was negatively associated and female sex (OR 2.9; 95% CI 1.6 to 5.0; p < 0.001) was 
positively associated with poorer Goldman scores (results not shown). 
Only 124 patients (male= 88, female= 36) were followed for four years. Women in this 
group continued to have significantly reduced functional capacity but equal proportions of 
men (23.5 %) and women (25 %) attributed the activity limitation to angina 
Table 14. Gender and Functional Capacity During 36 Months of Follow-up 
Goldman Seore > 2 MaBeN(%) FemaleN(%) .P value 
6months 134 (40.7) 95 (74.2) < 0.001 
Umontbs 117 (36.9) 89 (71.7) < 0.001 
24months 121 (39.5) 83 (68.5) < 0.001 
36 months 112 (38.8) 82 (73.2) <0.001 
Table 15. Gender and Cause of Activity Limitation During 36 Months of Follow-up 
Six months post-MI 
Cause MaleN{%) FemaleN (%) .r value 
Angina 73 (21.4) 29 (21.8) NS 
Dyspnea 69 (21.2) 38 (29.5) NS 
Fatigue 32 (16) 29 (22.5) NS 
Doctors advice 31 (15.7) 26 (20.3) NS 
Other 87 (26.6) 58 (45.3) < 0.001 
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Table 15 (cent). Gender and Cause of Activity Limitation During 36 Months of Follow-
up 
Twelve months post-MI 
Cause MaleN(%) FemaleN (%) Pvalue 
Angina 72 (22.1) 37 (29.8) NS 
Dyspnea 70 (22) 47 (38.2) < 0.001 
Fatigue 57 (17.9) 40 (33.3) < 0.001 
Doctors adviee 33 (10.5) 30 (25.2) < 0.001 
Other 76 (24.1) 50 (41.3) < 0.001 
Twenty-four months post-MI 
Cause Male N (l'lo) FemaleN (%) P value 
Angina 69 (22) 35 (28.7) NS 
Dyspnea 93 (30.5) 43 (35.3) NS 
Fatigue 51 (16.7) 38 (31.4) 0.001 
Doctors advice 11 (3.6) 9 (7.5) NS 
Other 67 (22) 45 (37.2) 0.001 
Thirty-six months post-MI 
Cause MaleN(%) FemaleN (%) Pvalue 
Angina 78 (26.8) 42 (36.5) 0.04 
Dyspnea 76 (26.4) 45 (39.8) 0.007 
Fatigue 34 (11.8) 31 (27.4) < 0.001 
Doctors advice 12 (4.2) 17 (15) < 0.001 
Other 81 (28.2) 49 (43.4) 0.004 
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3.1.6.4 Treatment During Follow-up · 
Except at thirty-six months follow-up, when men were significantly more likely to be 
prescn"bed ASA, the rate of ASA prescription remained constant and no gender difference 
in ASA use was seen. There appeared to be a relationship between symptoms and 
prescriptions throughout most of the follow-up period. Reflecting the clinical picture in 
terms of angina, and dyspnea six months following MI, there was no difference in medical 
thenJ,PY with respect to gender. At twelve months, women reported significantly more 
dyspnea and fatigue, and significantly more ACE-inhibitors were prescn'bed to women. At 
twenty-four months, activity limitation was not related to dyspnea or angina and there was 
no difference in prescriptions between men and women. Thirty-six months following MI 
was the exception. Women again suffered significantly more activity limitation due to 
angina, dyspnea, and fatigue and this was reflected only in the prescription of significantly 
more calcium channel blockers to women (see Table 15 and 16). 
Table 16. Gender and Pharmacotherapy During 36 Months of Follow-up 
ASA 
Timeline Male N (%) FemaleN (%) Pvalue 
6 months post-MI 251 (78.7) 96 (75.6) NS 
U months post-MI 254 (79.9) 96 (78) NS 
24 months post-MI 246 (81.7) 93 (79.5) NS 
36 months post-MI 236 (85.8) 35 (77.3) 0.04 
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Table 16 (coat). Gender and Pharmacotherapy During 36 Months of Follow-up 
Beta-blockers 
Time tine MaBeN(%) FemaleN (%) Pvalue 
6 mouths post-MI 133 (41.7) 51 (40.2) NS 
12 months post-MI 122 (38.4) 56 (45.5) NS 
24 months post-MI 120 (39.9) 48 (41) NS 
36 months post-MI 117 (42.5) 41 (37.3) NS 
ACE inlnbitors 
Timeline MalleN(%) FemaleN (%) P value 
6 months post-MI 89 (27.9) 44 (34.6) NS 
12 months post-MI 87 (27.4) 48 (39) 0.017 
24 months post-MI 95 (31.6) 37 (31.6) NS 
36 months post-MI 94 (34.2) 42 (38.2) NS 
Calcium Channel Blockers 
Timeline MaleN(%) FemaleN (%) Pvalue 
6 months post-MI 115 (36.1) 51 (44.9) NS 
12 months post-MI 106 (33.3) 51 (41.5) NS 
24 months post-MI 102 (33.9) 45 (38.5) NS 
36 months post-MI 86 (31.3) 50 (45.5) 0.01 
3.1.6.5 Iavasive mterveatioa duriag follow-up 
With respect to gender, there was no difference in the rate of CA or 
coronary revascularizatio~ when CABG and PTCA were separate, or combined, 
throughout the entire follow-up period (see Table 17). However, the number of patients 
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revascuJarized may have been too small to detect a statistically significant difference. 
Table 17. Gender and Invasive Intervention During 36 Months of Follow-up 
6 months post MI 
.Procedure MadeN(%) FemaleN (%) .P value 
CA 46 (13.3) 19 (14.3) NS 
CABG 25 (7.2) 4 (3.0) NS 
.PTCA 16 (4.6) 4 (13) NS 
Revascularized 38 (11) 8 (6.1) NS 
12 months post MI 
.Procedure MaleN(%) FemaleN (%) .P value 
CA 15 (4.6) 5 (4) NS 
CABG 5 (1.5) 3 (2.4) NS 
.PTCA 3 (0.9) 2 (1.6) NS 
Revascula'rized 8 (2.5) 5 (4) NS 
24 months post MI 
Procedure MaleN (%) FemaleN (%) .P value 
CA 13 (4.1) 2 (4.2) NS 
CABG 5 (1.6) 1 (0.8) NS 
.PTCA 3 (0.9) 3 (2.4) NS 
Revascularized 6 (1.9) 3 (2.4) NS 
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Table 17 (cent). Gender and Invasive Intervention During 36 Months of Follow-up 
36 months post MI 
Procedure Male N (%) FemaleN (%) Pvaiue 
CA 6 (2.0) 2 (1.7) NS 
CA.BG 1 (0.3) 0 NS 
PTCA 3 (1.0) 0 NS 
Revasewarized 4 (1.4) 0 NS 
3.1.6.6 Mortality 
Table 18 demonstrates that the rate of in-hospital mortality was significantly higher in 
females than in males. Muhiple logistic regression analysis of baseline clinical 
characteristics showed that age ~ 65 years was the only independent predictor of in-
hospital mortality (OR 2.6, 95% CI 1.4 to 4.9, p = 0.002) following AMI. A trend for 
increased mortality in females persisted throughout follow-up but did not reach statistical 
significance until36 months when 24 % of males and 32.4 % of females had died. 
When time to death was examined as an endpoint, Kaplan-Meier analysis showed that 
women had reduced likelihood of survival (Log rank statistic 8.31; p = 0.004) compared 
to men (See Figure 2). Multivariate Cox regression showed that a history of previous MI 
was a positive predictor for death (OR 1.9; 95%CI 1.1 to 3.4; p = 0.03). Those having 
previous MI were nearly twice as likely as those without MI history to die. Within the 
model, treatment with ACE inhibitors (OR 2.0; 95%CI1.2 to 3.6; p = 0.01) was a positive 
predictor of survival. Other variables entered into the analysis included sex, age, 
hypertension, diabetes, CHF, previous angina, recurrent MI, recurrent angina, post-MI 
CHF and treatment with ASA, beta-blockers and calcium channel blockers, none of which 
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were predictors for survival 
Gender and SuNWI Following AMI 
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Figure 1. Cumulative probability of survival for women and men following AMI 
Table 18. Comparison of Cumulative Mortality Rates by Gender 
Time post-MI MaleN(%) FemaleN (%) Pvalue 
In hospital 36 (7.4) 27 (12.6) 0.03 
6months 60 (12.4) 35 (16.4) NS 
12 months 73 (15.2) 43 (20.1) NS 
24 months 92 (19.2) 55 (25.7) NS 
36 months 114 (24) 69 (32.4) 0.02 
48 months 125 (25.8) 73 (34.1) 0.03 
As seen in Table 18, within four years following MI~ 125 men and 73 women were dead. 
A greater percentage of female deaths were cardiac in origin (69.8% versus 61.6 %) but 
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this was not .statistically significant. When cardiac death was subdivided, it was evident 
that a significant majority of female deaths were secondary to acute MI. Aside from MI 
no gender difference was seen in cause of death (see Table 19). 
Table 19. Cause of Cardiac Death by Gender 
Cause of Death MaleN(%) FemaleN(%) Pvalue 
AcuteMI 16 (17) 17 (32.1) 0.04 
CHF 33 (35.1) 19 (35.8) NS 
Arrhythmia 16 (11) 8 (15.1) NS 
Procedural 6 (6.4) 2 (3.8) NS 
Other Cardiae 6 (6.4) 5 (9.4) NS 
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3.2 Gender and Appropriateness of CoroRBary Artery Bypass Grafting in 
Newfoundland and Labrador (NLCABG Study) 
3.2.1 Context 
Between and within country differences in CABG rates render it difficult to determine the 
optimal rate at which to apply this treatment to patients with CVD. Limitation in 
government funding may interfere with ability to deliver optimal rate of CABG. Perhaps 
women fare worse than men in distribution of limited health care resources. 
3.2.2 Objeetive 
To determine if gender is associated with inappropriate use of surgical revascularization in 
NL. 
3.2.3 Hypothesis 
Male gender is associated with inappropriately high use of CABG in NL. 
3.2.4 Methods 
These data were originally collected in the context of the Coronary Artery Bypass 
Grafting in Newfound.Jand (CABG) study and subsequently stratified by sex and 
reanalyzed for the purpose of this study. The CABG study was undertaken at the request 
of the Health Care Corporation of St. John's to assist in decisions regarding the allocation 
of resources for the CABG program in NL. 
To determine annual need for CABG, all patients who had cardiac catheterization in St. 
John's in one year (Aprill994 -Aprill995) were identified. Those with significant disease 
on CA were divided into those referred for PTCA, considered inappropriate for 
revascuJarization, and those in whom CABG was feasible. Those without CAD and those 
with non-critical stenosis (<50 % LAD stenosis, < 70 % stenosis of other vessels) along 
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with those referred for angioplasty (other than failed angioplasties) were excluded. This 
study included those who were referred for CABG after coronazy angiography and those 
who were on the waiting Jist for CABG and underwent the procedure during the study 
period. 
Chart reviews using cardiac catheterization report, hospital chart, cardiologists' chart, and 
minutes :from weekly cardiac surgery conferences were undertaken. Data abstracted 
included CAD risk factors, angina symptoms, indication for CABG, coronazy anatomy, 
ejection :fraction, medical therapy, operative risk and contraindications to surgery, and 
postoperative complications. Refer to Appen.dix 2 fur definitions of terms used to 
descnbe patients. 
Using the guidelines of a Canadian panel (McGlynn, Naylor, Anderson et al, 1994; Naylor, 
McGlynn, Leape et al, 1993), each patient was assigned appropriateness and necessity 
scores from 1-9. Appropriateness was defined to mean that expected benefit exceeded 
expected negative consequences by a margin that made treating physicians believe that 
surgery was worthwhile. Necessity was defined to mean that the physician felt obligated 
to offer the surgical option to the patient as the best clinical option available given that 
there was a high probability of benefit in patients with similar presentation. 
Appropriateness ratings tend to err on the side of intervention, whereas necessity ratings 
provide a more stringent risk-benefit ratio. 
Appropriateness score is based on a scale of one to nine, with one being extremely 
inappropriate and nine being extremely appropriate. GenemlJy a score of one to three is 
considered inappropriate, four to six intermediate, and seven to nine appropriate. 
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Necessity score is based on a scale of one to nine, with one being extremely unnecessary 
and nine being extremely necessary. Generally a score of one to three is considered 
unnecessary, four to six intermediate, and seven to nine necessary. 
3.2.5 Statistical Analysis 
The study population was stratified by gender. Differences between males and females 
were evaluated for statistical significance by the Chi-square statistics for discrete variables 
and by t-test for continuous variables. A p value ofless than 0.05 was considered to 
indicate statistical significance for all comparisons in this study. The SPSSX statistical 
package was used for all statistical analysis. 
3.2.6 Results 
3.2.6.1 Demographics 
For 338 of342 patients there was information on clinical presentation, medical treatment, 
coronary anatomy, cardiac function, ischemic risk and operative risk. Males comprised 
72% of the group. Females were significantly older than males with average ages being 
65 (± 9) and 59 (± 1 0) years respectively. 
As shown in Table 20, women suffered significantly more severe angina symptoms prior to 
coronary angiogram. Eighty-nine percent of women and 79 % of men had Class IV 
angina. However there was no gender difference in application of maximal medical 
therapy. There was no gender difference in thrombolytic use, frequency ofMI, or results 
of exercise stress tests prior to coronary angiogram. 
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Table 20. Gender, Demographic and Clinical Characteristics and Treatment Prior to 
CA 
Factor 
Previous MI 
Class IV Angina 
Thrombolytic 
Maximal Medical 
Therapy 
Strongly positive stress 
test 
MaleN(%) 
148 (61) 
191 (78.9) 
17 (7) 
203 (83.8) 
122 (85.9) 
FemaleN (%) 
48 (50) 
85 (88.5) 
14 (6) 
86 (89.5) 
39 (82.9) 
PvaBue 
NS 
0.01 
NS 
NS 
NS 
The majority of patients, regardless of sex were referred for CABG due to unstable angina 
with 790A, of women and 73% of men having this documented as the indication for CABG 
(See Table 21). 
Table ll. Gender and Indication for CABG 
Indication MaleN(%) FemaleN(%) Pvalue 
Chronic Stable Angma 25 (10.3) 9 (9.4) NS 
Unstable Angina 176 (72.7) 76 (79.2) NS 
PostMI 26 (10.7) 7 (7.3) NS 
As shown in Table 22, there was no gender difference in severity of CAD on coronary 
angiogram. Eighty-eight percent of men and 91 % of women had significant CAD defined 
as double vessel disease involving the proximal left anterior descending artery (LAD), 
triple vessel disease or left main disease. Groups were also similar in terms ofleft 
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ventricular function measured on coronary angiogram (see Table 23). 
Table 22. Gender and Angiographic Findings 
Finding MaBeN(%) FemaleN(%) f'valne 
Left Main Disease 49 (20.2) 14 (14.5) NS 
3 Vessel Disease 130 (53.7) 59 (61.4) NS 
2 Vessel Disease with 35 (14.5) 14 (14.6) NS 
LAD 
1 Vessel Disease 20 (8.3) 4 (4.2) NS 
without LAD 
1 Vessel Disease 6 (3.3) 5 (5.2) NS 
EF<35% 61 (25.4) 23 (23.9) NS 
Table 23 shows that a significantly higher number of women were considered to be at 
greater operative risk than men. Fifty percent of females and 30 % of males were at 
moderately high to very high operative risk. 
Table 23. Gender and Operative Risk 
.Risk Group Male N (%) FemaleN (%) f' wine 
Normal/low 169 (69.8) 48 (50) < 0.001 
Moderately high 55 (22.7) 30 (31.2) <0.001 
Very high 18 (7.4) 18 (18.7) < 0.001 
There were no cases in which surgery was considered inappropriate. There was no gender 
difference in appropriateness score or necessity score. More than 96 % of surgeries in 
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females and 99 %of surgeries in males were considered highly appropriate with 
appropriateness score of at least seven. More than 92 % of surgeries in females and more 
than 94 % of surgeries in males were considered highly necessary with necessity scores of 
at least seven. The remaining surgeries were considered to be of intermediate risk and 
necessity (see Table 24). 
Table 24. Gender and Appropriateness/Necessity of CABG 
Score 
Appropriateness ?! 7 
Necessity > 7 
MalesN(%) 
241. (99.5) 
228 (94.2) 
Females N (o/o) 
93 (96.8) 
89 (92.7) 
Pvalue 
NS 
NS 
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4 Discussion and Conclusions 
4.1 NLMI stu.dy 
The NLMI study population was demographically similar to other studied populations in 
many ways. Women were older and had more diabetes and hypertension (see Table 1) 
prior to study entry. Similarly, men were significantly more likely to be smokers and to 
have angiographic evidence of CAD prior to MI (Greenland, Reicher-Reiss, Goldbourt, 
Behar et al, 1991; Steingart et a1, 1991; Rathore et a1, 2002; Mueller et a1, 2002). Men 
were significantly more likely than women to have had CABG prior to the current Ml 
(Mueller et a1, 2002; Azar et a1, 2002). Men were more significantly more likely than 
women to have Q-wave infarcts involving the anterior cardiac wall. Women also suffered 
more recurrent angina, recurrent MI, and a higher incidence of moderate to severe CHF 
and were more likely than men to die during the immediate post-MI period (Maynard et a1, 
1992, Becker et a1, 1994; Jenkins et a1, 1994; Greenland et a1, 1991). 
Comparing men and women in NL reveals some important gender differences in clinical 
characteristics and management. Despite increased likelihood to suffer ischemic 
complications and death in hospital, women in the MI study received medical intervention 
that was similar to that of men and invasive assessment and intervention that was less 
aggressive than that provided to men (see Table 5 and Table 11 ) .. While older age was 
associated with less aggressive intervention, gender was not an independent predictor of 
noninvasive treatment once age was taken into account. The opposite was true when CA 
and coronary revascu1arization were considered. Younger age and male sex were strong 
independent predictors of invasive assessment and intervention. Long-term mortality was 
higher and functional limitation was greater in women than men. 
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Several studies have reported improved survival in association with frequent use of 
pbannacologic and invasive interventions in MI patients (Pfeffer et al, 1992; The SOL VD 
investigators, 1992; Clarke et al, 1994; Tsuyuki et al, 1994; Rouleau et al, 1996). 
Underutiliza.tion of proven efficacious post-MI therapies has likewise been the finding of 
several studies (Rouleau et al, 1993; Clarke et al, 1994; Wilkinson et al, 1994; Tsyuki et 
al, ·1994). Many studies have reported gender differences in~ use of standard post-MI 
medical therapies (Clarke et al, 1994; Sial et al, 1994; Tsuyuki et al, 1994; W:illdnson et al, 
1994, Chu et al, 1998). Consistent with the findings of these studies, NLMI women were 
significantly less likely than men to receive heparin (Chandra et al, 1998) following MI. 
Like the NLMI study, these studies were conducted in the early 1990's and included 
consecutive patients with definite diagnosis of acute MI. This should reduce the impact of 
temporal trends and selection bias in the application of standard therapies between these 
studies and the NLMI study. 
It is evident that, with the exception ofpost-MI beta-blockers, NL patients are treated 
similarly to other Canadian patients. For example, F ASTRACT TI (Heart and Stroke 
Foundation of Canada, 1999) showed that in 1998, in Canada, 46.3% of patients were 
prescn"bed ACE-inln"bitors, 72.9 % were prescn"bed beta-blockers and 82.7 % were 
prescn"bed ASA following AMI (Heart and Stroke Foundation of Canada, 1999). The 
CAMI study, like the NLMI study, reflects prescribing patterns in the early 1990's, 
thereby accounting for temporal trends and changes in post MI treatment. It shows that, 
following AMI, 24% of Canadian patients were prescribed ACE-inln'bitor, 61% were 
prescn'bed beta-blockers and 86 % were prescn"bed ASA (Rouleau et al, 1996). In 
comparison, following AMI, 22.5 % ofNL patients were prescribed ACE-inhibitors, 28.5 
%were prescn"bed beta-blockers and 78.5 %were prescn'bed ASA (see Table 5 and Table 
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25). 
Table 25. Comparison o[Post-MI treatment in Canada versus N L 
Source Fastraek ll CAMI 
Year 1998 1990 to 1993 
Population 
%ACE 
%BB 
%ASA 
Canadian 
46.3 
72.9 
82.7 
Canadian 
24 
61 
86 
NLMI 
1990-1993 
Newfoundland & 
Labrador 
22.5 
28.5 
78.5 
* CAM/= Canadian Assessment of Myocardial Infarction; NLMI =Newfoundland and Labrador MI 
study; ASA = Acetylsalacylic Acid; BB = beta-blocker; ACE = angiotensin converting enzyme inhibitor. 
While it appears that appropriate CHF treatment is not reflected in ACE-inlnbitor 
utilization, this probably reflects a temporal trend in the data. Studies OfLeft V entricu1ar 
Dysfunction (SOL VD) investigators reported that, from 1988 to 1989, the overall 
utilization rate for ACE-inhibitors in CHF treatment was only 30 % (Bourassa, Gurne, 
Bangdiwa1a et at, 1993), and Martinez et al reported only 23 %use in post-MI patients in 
1994 (Martinez et at, 1998). Therefore, apparent low ACE-inlnbitor utilization in the 
NLMI study may simply reflect practice patterns in the early 1990's. This is supported by 
comparable ACE inlnbitor utilization in the CAMI study (Rouleau et at, 1996). SOL VD 
investigators did find higher utilization of ACE-inlnbitors in more seriously ill patients 
(Bourassa et at, 1993). Twenty-four percent of women and 22% of men in the NLMI 
study received ACE-inhibitors, while 22% of women and 12% of men in the NLMI study 
had more severe CHF. This is more in keeping with findings of the SOL VD investigators 
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in this subpopulation. Studies of ACE-inhibitor utilization in post-MI patients with left 
ventricular dysfunction were ongoing at the study center at the same time as the NLMI 
study. This may have favorably impacted ACE-inhibitor administration in patients with 
more severe CHF by influencing the rate at which research findings were incorporated into 
clinical practice. 
The rate of beta-blocker use in the NLMI study is dramatically lower than that of the 
CAMI study (Rouleau et al, 1996). At least one other study has reported utilization of 
beta-blockers that was comparable to that seen in the CAMI study during the same time 
period (Martinez et al, 1998). In the NLMI study, historic CHF or diabetes were not 
related to beta-blocker utilization. However, there was a statistically significant 
relationship between post-MI CHF and beta-blocker admin1stration thus providing some 
explanation for the low rate ofbeta-blocker use. 
While, with the exception of heparin, no gender difference was seen in medical 
intervention in the NLMI study. One could argue that since women bad bad higher post-
MI complication rates, they should probably have received IV thrombolytics, IV 
nitroglycerine, and IV heparin more frequently than men. However, since multiple logistic 
regression analysis revealed that sex was not an independent predictor for receiving any of 
these treatments, it appears that patient characteristics, rather than gender, provide an 
explanation for apparent underutilization in females with complicated post-MI courses. 
Consistent with the findings of many other studies (Tobin et al, 1987; Ayanian et al, 1991; 
Steingart et al, 1991; Krumholz et al, 1992; Maynard et al, 1992; Bickell et al, 1992) 
including Canadian studies (Jaglal et al, 1994; Naylor et al, 1994) women in the NLMI 
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study were less likely than men to undergo invasive investigation following MI. Contrary 
to the recommendations of the ACC/AHA TF (Ryan et ~ 1996), which suggests CAin 
patients with post-MI courses complicated by recurrent angina, recurrent MI and L VD, 
females were significantly less likely than men to have invasive investigation in the 
immediate post-MI period despite a significantly greater incidence of these exact 
complications. 
After adjustment for demographic and clinical variables, male gender was reduced to 
borderline significance as an independent predictor for CA following MI. Controlling for 
clinical variables has produced similar results in other studies (Krumholz et ~ 1992; 
Wong et ~ 2001; Rathore et ~ 2002). Unlike the studies of Tobin and Ayanian (Tobin 
et ~ 1987; Ayanian et ~ 1991), these studies, and the NLMI study, were all undertaken 
in patients with definite evidence of acute MI. All patients included in these studies were 
likely to have ischemic heart disease; therefore presumptions about pre-test likelihood of 
CAD should not have influenced the decision to refer patients for coronary angiography. 
Controlling for post-MI complications increased the significance of male sex as an 
independent predictor of CA Men were 80 % more likely than women to undergo CA 
during the post-MI period. This seems to suggest the presence of gender bias in referral 
of patients for CA. Previous data sets have not been analyzed in this fushion. 
Twenty five percent of the patients included in our study were transferred from another 
facility. Because transfers are often made with further intervention in mind (Paul et ~ 
1995), this group may include patients with larger or more complicated MI's and may 
increase the rate of referral for CA. However, the CA referral rate was comparable to 'that 
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of Krumholz and colleagues who received equal number of referrals :from family 
practitioners and specialists (Krumholz et al, 1992) and less than that ofWong and 
colleagues who included only patients with cardiogenic shock following MI (Wong et a1, 
2001). 
Some studies suggest equal utilization of revasculari.21ltion following coronary angiograms 
(Tobin et al, 1987; Bergelson et al, 1996; Bell et al, 1995; Wong et al, 2001; Ghali et al, 
2002), but this was not the case in the NLMI study. These studies include a variety of 
patients with a variety of reasons for referral to CA During post-MI hospitalization, NL 
men were significantly more likely than women to be revascularized. Even after controlling 
for a variety of clinical characteristics, men were more than twice as likely as women to be 
revascularized. In an Ontario study, Jaglal et al, also found that men were twice as likely 
as women to be revascularized in the post-MI period (Jaglel et al, 1994). In an Alberta 
study, adjustment for severity of CAD eliminated gender differences in referral to 
revascularization, however the study popuJation included a cohort of patients referred to 
CA. This popuJation differs from the NLMI study popuJation who all bad definite 
diagnosis ofML Access to detailed clinical data, particularly on severity of vessel disease, 
may have eliminated this gender difference in the NLMI population (Ghali et al, 2002). 
Krumholz and others found that even after controlling for age and severity of coronary 
artery disease on CA, there remained a borderline significant lower rate of CABG in 
females. Like the NLMI study, Krumholtz included post-MI patients rather than patients 
presenting with suspected cardiac ischemia (Krumholz et al, 1992). Unfortunately we do 
not have data on severity of vessel disease and are unable to determine the impact on 
referral to revascularization. Krumholtz however did not have information on clinical 
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variables other than age and CAD severity and was unable to control for these 
confounders. 
Wong and colleagues and Steingart and colleagues have reported higher rates of 
revascularization in men and women; however both studies included highly selected 
population of patients (Wong et a4 2001; Stiengart et a1, 1991). In the SHOCK study 
patients had post-MI cardiogenic shock (Wong et a1, 2001), whereas in the SAVE study, 
only patients having post·MI L VD were included in the analysis (Steingart et a1, 1991 ). 
Unfortunately, there is no available information regarding disease severity in the NLMI 
population, and appropriateness of referral to revascularization cannot be determined. 
Newfoundland and Labrador's unique geography and population distribution has resulted 
in concentration of cardiac health care specialists and diagnostic facilities in the capital 
city. Like other Canadian provinces, Newfoundland and Labrador is experiencing 
increasing difficulty in providing necessary resources to meet demand for health care. 
Budgetary restraints impact patterns of practice by imposing limitations on availability of 
expensive procedures. The result is higher thresholds and longer wait lists for 
performance of these procedures (Rouleau et a1, 1993; :Bengston et a4 2000). However, it 
has been shown in at least one study that wait list time is similar for men and women 
(Bengsto~ 'Karlsson and Herlitz, 2000). 
Because referrals for invasive coronary procedures are received in only one tertiary care 
hospital in NL, they are performed by priority and dependent on wait lists. Wait lists are 
growing and even very urgent cases are not receiving procedures within the recommended 
timeframes (Cohe~ Ivanov, Weisel, Rao and Borger, 1996; Fox, O'Dea and Parfrey, 
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1998). It has been demonstrated that only 23 %~ 24% and 64 %respectively ofNL 
patients in whom CABG was considered very urgent (within 24 hours), urgent (within 72 
hours), or semi-urgent (within 14 days and during the same hospital stay), underwent the 
surgery within the recommended time (Fox et ~ 1998). Because the NLMI study was 
conducted at this same tertiary hospital, and based on prolonged wait times for even very 
urgent cases, it would seem logical to perform fewer invasive procedures on stable 
patients on initial admission fur AMI. 
Due to limitation ofhealth care resources in NL (Fox, O'Dea and Parftey, 1998), those 
revascularized during MI admission should probably represent the most severe cases, but 
without information regarding vessel disease, surgical appropriateness, or necessity, this 
cannot be stated with certainty. Fox et al have demonstrated that, of those NL patients . 
categorized for placemen~ on the short wait (within 6 weeks) or delayed elective (within 6 
months) wait lists, 50 % and 75 %respectively underwent CABG within the 
recommended time (Foxet ~ 1998). 
During follow-up, intensification of medical therapy appeared to be symptom-driven, as 
severity of angina and dyspnea were closely related to prescription of appropriate medical 
interventions. Throughout three years of follow-up, women continued to demonstrate 
poorer functional class than men. Dyspnea and fatigue were key contributors to increased 
Goldman scores. There is a paucity of data on functional limitation in post-MI patients so 
it is difficult to compare these findings to other studies. 
Despite having no knowledge of Goldman scores, physicians prescribed beta-blockers and 
ACE inlnoitors appropriately, according to the documented reason for activity limitation 
68 
on the Goldman scale. Calcium channel blockers were added to the regime at thirty-six 
months post-MI, when women reported that angina was a significant limitation to activity. 
· It is unclear whether these were being used in lieu ofbeta-blockers for angina control in a 
female population, of whom 22 %were suffering from moderate to severe CHF (see Table 
15 and Table 16). 
A lower rate of invasive intervention has been shown to be associated with activity-
limiting angina (Rouleau et a.1, 1993; Marl, et a.1, 1993). Bickell and others suggest that 
referral oflow risk males for bypass could result in improved quality of life (Bickell et a.1, 
1992). In keeping with these findings, Goldman scales provide evidence of significantly 
greater female disability from angina symptoms at thirty-six months following MI. 
Two studies have reported that higher rates of invasive diagnostic and therapeutic 
interventions in the United States (compared to Canada), did not impact rein:fi:lrction or 
survival in post MI patients (Rouleau et a.1, 1993; Mark, Naylor, Ca.lifl: et a.1, 1993). 
Conversely, the CAMI study report indicated that revascuJariza.tion was inversely related 
to mortality (Rouleau et a.1, 1996). The SAVE study included only those MI patients who 
had resolved ischemic events prior to the necessary randomization period .. This was only a 
small proportion of all MI patients and may have resulted in reduced mortality in the 
SAVE study (Rouleau et a.1, 1993). 
Following the index MI, there was no gender difference in rate of readmission to hospital 
In the absence of mortality data this may seem to justifY the more aggressive treatment of 
angina with revascularization in men. Assessment of mortality data however, reveals 
significantly poorer survival and a higher number of fatal out-of-hospital MI's in women. 
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With the absence of information regarding disease severity on CA or appropriateness of 
revascularization in this population, and are unable to determine whether these women 
were likely to have benefited from more aggressive intervention. However after 
controlling for clinical variables, revascularization was the only post-MI treatment to be 
related to sex. 
The overall rate of in-hospital mortality was comparable that of an identical Canadian 
population, with the NL in-hospital death rate being 10.4 ·% and the Canadian in-hospital 
death rate being 9.9 %, as reported by Rouleau in the CAMI study. As with the CAMI 
study, in-hospital female mortality approximately doubled that of males and was 
statistically significant in both studies. The Canadian female mortality rate was 15.7 % 
compared to the male mortality rate of7. 7 %. The NLMI female mortality rate was 12.6 
%compared to the male mortality rate of7.4% (Rouleau et al, 1996). 
As both the NLMI study and the CAMI study are population-based including consecutive 
MI patients, selection biases inherent in clinical trials are reduced. It is expected that 
mortality in a population study would be higher than that seen in a highly selected clinical 
trial population (Naylor and Chen, 1994) such as the SAVE study. This probably explains 
comparable mortality in the NL study and the CAMI study and higher mortality than the 
SAVE study. 
Mortality, one year following MI, was substantially higher in the NLMI population than in 
the overall Canadian population (16.5% versus 7.1 %). Although cumulative mortality 
rates were consistently higher in females, no gender difference was seen in post-MI 
mortality in the NL population until three years post-MI when a significantly greater 
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number of deaths were seen in women (Table 18). Unfortunately, no comparable data is 
available for the Canadian population. While the ~AMI study concludes that female 
gender is associated with increased in-hospital but not post-discharge death, the NLMI 
study suggests that, while there is no gender difference in short-term survival post-
discharge, in hospital and long-term survival(~ 2 years) is significantly poorer in women 
than men. Patients in the CAMI study were followed for only one year and mortality 
results in the NLMI study at one year, similarly showed no significant difference in 
mortality by gender. Similar results may have been yielded in the CAMI study with longer 
follow-up. Female longevity dictates that longer trials are needed when comparing 
mortality in m.en and women (Merz, Johnson, Kelsey et al, 2001 ). Conversely, perhaps 
female mortality is related to lower rates of revascularization in females in the NLMI 
study. 
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4.2 NLCABG Study 
The NLCABO study population is comparable to similar populations in several ways. 
This study demonstrates poorer clinical condition in women at time of coronary 
angiogram. Women were older and significantly more likely than men to have Class IV 
angina at time of presentation. However, there were no gender differences with regard to 
treatment with maximal medical therapy or thrombolytics, and women were no more likely 
than men to have had a previous MI or a strongly positive stress test prior to angiography. 
There were no gender differences in indication for surgery or in severity of vessel disease 
on coronary angiogram. A significantly greater number of women than men were at 
moderately high, to high operative risk. Appropriateness and necessity scores were high 
regardless of sex. 
The proportion of females receiving CABO in NL was slightly higher (27 %) than that of 
Ontario or British Columbia (20 % versus 23 % respectively) in a study by Anderson and 
colleagues (Anderson et al, 1997). The results were similar for another Ontario study in 
which nineteen percent of those revascularized were female (Abramov et al, 2000). This 
may simply reflect the higher prevalence of CAD in NL females (Heart and Stroke 
Foundation, 1999). 
Consistent with the findings of the NLCABO study, other studies have shown women to 
be older (Anderson et al, 1997; Aldea et al, 1999; Tan et al, 1999; Aquilar, Lazaro, Fitch 
et al, 2001) and to have more severe angina when presenting for revascularization (Aquilar 
et al, 1997, Tan et al1999; Abramov et al, 1999). Similarly to study populations of 
Aquilar, Tan and Abramov the NLCABO study population was a retrospective cohort 
selected after CABO was performed. Since these populations have undergone CABO, it 
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is more likely that they are suffering from advanced CAD. These popu1ations cannot be 
considered representative of all patients with CAD (Aquilar et al, 2001). Older age and 
severity of angina in females may indicate that women were referred for revascularization 
when coronary disease was more advanced. These findings are supported by several other 
studies suggesting later referral in women (Kee et al, 1995; Aguilar et al, 2001). 
Newfoundland and Labrador patients have more severe angina than patients referred for 
CABO in other Canadian provinces. In the NLCABO study, there was no gender 
difference in indication for CABO with 79.2 % of women and 72.7 % of men being 
referred to CABO because of unstable angina, while 9.4% of women and 10.3% of men 
were referred to CABO for chronic stable angina. The finding of gender similarity in 
surgical indication has been seen in other studies of revascularized patients (Aquilar et al, 
2001; Roeters van Lennep, 2000). Compared with Ontario and British Columbia data on 
main indication for CABO, a much higher proportion ofNL patients were referred for 
CABO due to unstable angina. Seventy-seven percent ofNL patients were referred to 
CABO because of unstable angina compared to 43 % for British Columbia (BC) patients 
and 20% for Ontario (ON) patients (Anderson et al, 1997). The definition of unstable 
angina was the same in the NL study and the ON/BC study. Differences in indication for 
revasculaization between the Ontario and British Columbia population and the NLCABO 
population suggest provincial differences in the management and referral of patients. 
Eighty-eight percent of men and 91 %of women in the NLCABO study had multivessel 
disease involving the left main coronary artery or the proximal left anterior descending 
artery. Gender similarity in the extent of vessel disease has been duplicated in other 
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studies of revascularized patients (Aquilar et a4 2001; Roeters van Lennep, 2000). 
In the NetherJands study of patients refurred fur CA over a sixteen-year period, no 
difference was seen in. the extent or location of coronary artery lesions (Roeters van 
Lennep et a4 2000). In that study, referral to revascularization was associated with the 
extent of disease, which we are unable to determine in the NLCABG population, as the 
cohort was formed after refurral for CABG. In contrast, .Krumholtz and colleagues found 
that women had a significantly lower rate of severe CAD (OR 0.67), defined in the same 
way as the NLCABG study. However, Krumholtz included consecutive patients with 
AMI and the NLCABG study and the study of Aquilar and colleagues included cohorts of 
revascularized patients (Krumholtz et at, 1992; Aquilar et a4 2001). While, patients in 
Krumholtzs' study had a high probability of CAD, the selection process inherent in referral 
for CABG would probably dictate that NL patients have more severe vessel disease. 
It has been shown that women have much higher surgical risk than men at the time of 
revascularization (Aquilar et at, 2002). This is likewise the finding of the NLCABG study. 
This strengthens evidence for later referral in women. 
In NLCABG, there was no evidence of inappropriate referral for surgical 
revascularization, regardless of gender. This is consistent with other studies reporting that 
coronary revascularization does not tend to be overused following CA (Leape et a4 1993; 
McGlynn et a4 1994). In fact substantial underuse has been documented in patients 
considered appropriate for these procedures (Hemingway, Crook, Feder et a4 2001 ). 
A Swedish study showed that eight percent of patients referred to continued medical 
therapy met necessity criteria for CABO (Bernstein. et a4 1999). In a study by 
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Hemingway and others, 26% of those considered appropriate for CABO received only 
medical treatment. These patients were more likely to have angina, non-mtal MI, or 
death than those who underwent CABO (Hemingway, Crook, Feder et a1, 2001). Another 
study in the United Kingdom, demonstrates strong association between severity of vessel 
disease, appropriateness, and treatment (Hemingway, Crook, Dawson et a1, 2001 ). These 
studies provide strong support for clinical validity of appropriateness ratings for referral to 
revascularization (Hemingway, Crook, Feder et a1, 2001; Hemingway, Crook, Dawson et 
a1, 2001; Bernstein et a1, 1999). 
Appropriateness of referral for CABO tends to be high (Leape et a1, 1993; Naylor et a1, 
1994). More than 96% of female referrals for procedures and more than 99% of male 
referrals for procedures in the NLCABO study were considered highly appropriate. 
Likewise necessity scores exceeded North American averages of 70 % to 83 % (McGlynn 
et al, 1994). More than 92% of female procedures and more than 94% of male referrals 
were considered highly necessary. In other North American studies, the reported rate of 
inappropriate use of revascu1arization has been between two and six percent (McGlynn et 
a1, 1994). A Canadian study of ON and BC patients reported 3.9% and 2.4% of CABO 
cases to be rated as inappropriate (Anderson et a1, 1997). A Sweedish study, using 
conservative definitions, estimated inappropriate use of CABO to be ten percent 
(Bernstein et a1, 1999), while a study in the Netherlands estimated that only four percent 
of CABO decisions were inappropriate (Meijler et a1, 1997). The difference in findings 
between these studies andNLCABG may lie simply in the population under study. The 
Swedish study findings are based on all patients referred for CA, while the Netherlands 
study findings and the NLCABO study includes all those being referred to or having 
undergone CABO. Comparison of appropriateness at time of revascu1arization might have 
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yielded similar rates of inappropriateness. 
Because only patients who were a1ready referred for CABG are included, NLCABO data 
do not allow for any assumptions about underuse of the surgical option. Given severity of 
angina and extent of vessel disease in those undergoing CABO, it is likely that the 
threshold for placement on the bypass list is high in NL. As the wait lists are long and 
growing, underuse is more likely to be the case. It has been demonstrated that coronary 
revascularization is underused in a population of CA patients in whom it was deemed to be 
highly appropriate (Hemingway, Croo~ Feder, et a4 2001). 
Likewise, the results of the NLCABO study indicate that, regardless of gender, the cardiac 
surgery program NL provides surgical intervention for patients in whom revascularization 
is highly appropriate and necessary. Despite being at significantly greater operative risk 
than men, women were offered and did accept the surgical option. Owing to wait lists and 
limited health care resources, these too probably represent the most urgent cases requiring 
CABO. 
Older age and more severe symptoms suggest re:fei:ral Jater in the disease process in 
women. It is arguable that based on symptom severity, women in the CABG study should 
have been referred for revascularization more often than men. Equal application of 
surgical intervention, despite more severe female symptoms, provides further support for 
reduced symptom-driven revascuJarit.ation in women in this study. Surgical 
revascularization in women ofhigh operative risk however, suggests physician support for 
the surgical option when symptoms and vessel disease are severe. 
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Delays in referral for revascularization may occur for many reasons including delayed 
seeking of medical attention by the patient, delayed referral for diagnostic tests, or delayed 
treatment once disease is identified. The CABG population represents a highly selected 
population having passed through several junctures in the referral process. This selection 
process may in fucthave served to reduce potential gender bias in this population. Using 
this data set the author was unable to determ.ine if late referral or treatment choices are 
based on patient or physician decision. 
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4.3Summary 
This review of two observational studies shows that, although not as dramatic as 
anticipated, there are some important gender differences in the treatment and clinical 
outcomes of patients with known cardiovascular disease in Newfoundland and Labrador. 
Differences in clinical characteristics :fully explain the differences in medical management 
in this patient population. However men were significantly more likely than women to 
have invasive assessment and to be revascularized following the index MI. Women had 
higher in-hospital and long-term mortality from cardiac causes. They also had consistently 
poorer functional capacity and activity limiting angina than men throughout the follow-up 
period. Among patients who were surgically revascuJa.rized in NL, there was no indication 
of inappropriate utilization of CABG. 
Pre-test likelihood of disease along with ACC/ AHA guidelines for post MI treatment 
(Ryan et al, 1996) suggest that referral to CA should occur in equal proportions regardless 
of gender. Higher referral in men after consideration of all demographic and clinical 
fu.ctors suggests gender bias in the NLMI study population. 
In the absence of information on disease severity in the MI population, we are unable to 
determine if they were surgical candidates. There are no published data addressing 
functional capacity and long-term activity limitation resulting from cardiac symptoms. The 
NLMI study is the first study having the ability to relate long-term functional capacity and 
mortality to cardiac intervention in such detail. The mortality and functional capacity data 
suggest underutilization of invasive interventions in NLMI women as opposed to over-
utilization in men. The result is higher in-hospital and long-term mortality, and significant 
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functional limitation in women. The results ofMLR showed that gender differences in the 
NLMI population were isolated to invasive intervention. 
Reduced qse of CA and myocardial revascularization in the NLMI study probably 
contnbuted to higher mortality particularly in females. Additionally, referral of a more ill 
female population for management of post MI complications may also have contributed to 
excess female mortality in this study. This is further supported by more severe angina and 
higher use of maximal medical therapy in females in the NLCABG study. Steingart and 
colleagues reported that drugs, rather than invasive interventions, were generally used to 
control cardiac complaints in women, even when their disability was greater than that of 
men (Steingart et al, 1991 ). Increased utilization of myocardial revascularization may 
have resulted in reduced mortality and improved quality of life in this patient population. 
The NLCABG population was a highly selected patient group as they were primarily 
referred for urgent or emergent surgeries. This selection process may in fuct have served 
to reduce potential gender bias in this population. However women were older and bad 
more severe angina therefore were probably referred at a later stage than men (Kee, 
1995). 
Knowledge and attitudes among general practitioners and internists or cardiologists affects 
patient referral (Kee, Gaflhey, Curry et al, 1993) and potentially other aspects of care. 
Rouleau and coworkers have suggested that marked bed restrictions increase the rate of 
definite MI admissions to Canadian versus US coronary care units (Rouleau et al, 1993). 
As observed by Every and colleagues, post MI patients are more likely to receive CA if 
they are admitted where facilities are available, than if they require transfer (Every, 
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Larso~ Litwin et al, 1993). Sumita and others have claimed that patients transferred from 
outside hospitals are primarily admitted in consideration of :further coronary intervention 
(Sumita et al, 1995). Kostis et al have suggested that women are less likely than men to 
be admitted to .a facility equipped to perform invasive procedures (Kostis et al, 1994). All 
of these findings indicate a high degree of selection in theCA and revascularization 
referral process. Provincial differences in angina severity on referral to CABG 
demonstrate that NL patients are probably referred to revascularization when angina is 
more advanced (Anderson et al, 1997). This is probably because of availability of fewer 
acute care beds, cardiac catheterization and revascularization facilities in NL. It is evident 
from the NLCABG study that the patients referred for myocardial revascularization 
represent a highly selected population of the most severe cases. 
It is clear that bias has the potential to influence all stages of referral in women who suffer 
from cardiovascular disease. Some selection bias has a1ready occurred before a patient 
presents for hospital care. Such bias may occur for many reasons, but geographic and 
health resource allocation limitations probably play a vital role in selecting the population 
in both the NLMI and NLCABG studies. 
From Sackett's table of selection biases (Sackett, 1979), three appear to be critical in 
defining the population included in these NL studies: 1) Centripetal bias may have 
influenced primary physicians to refer, or patients to gravitate towards, the only tertiary 
rererral center in NL; 2) Referral filter bias may have resulted in the selection of more 
complex cases or more ill patients for referral to tertiary care; 3) Diagnostic access bias 
may have bad an impact as geographic and economic access to diagnostic ·and invasive 
cardiac procedures is inequitably distnbuted. 
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In NL, gender bias is not evident in the medical management of post-MI patients. 
However in considering more invasive intervention, physicians are influenced by patient 
sex. Evidence suggests that quality initiatives may be useful in improving adherence to 
evidence-based guidelines (Haddad, Searles and Gillis, 2001). Adherence to clearly 
defined patterns of practice should improve the likelihood for patients to receive similar 
assessment and treatment regardless of gender. 
The NL studies have several strengths compared to other studies in this area: 1) While it 
was analyzed retrospectively, the NLMI data was collected prospectively and was not 
dependent on chart reviews; 2) The NLMI study has lengthy follow-up and detailed 
clinical, treatment, and outcome data, allowing us to be one ofthe first to assess functional 
capacity as it relates to medical and invasive intervention in these patients. 3) The 
NLCABG study was among the first to address gender and appropriateness of 
revascularization and is the first in NL to address this issue. 
Likewise these studies have some weaknesses: 1) The NLMI patients were a select group 
of patients who were enrolled in the SAGES study. Information on the overall population 
from which these 698 patients were selected is unavailable. Additionally, since a significant 
number ofNLMI patients were probably referred to the study fucilities because of post-MI 
complications, it is possible that selection of a higher risk female population has occurred 
through referral filte~ bias and diagnostic access bias. Likewise many of the NLCABG 
population was probably refereed fur consideration of invasive intervention resulting in 
selection of a population with more advanced CAD. Therefore it may not be appropriate 
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to generalize the results of these. studies to the remainder ofNewfoundland and Labrador 
or to other provinces in Canada The unique geographic distribution and availability of 
limited facilities for invasive intervention may affect treatment and influence outcomes in 
our studies. 2) These data are dated and in some cases are up to ten years old. The data 
do however help to fill a gap in the Canadian data, especially for this region. To avoid a 
disconnect between current consensus and decade-old thinking on appropriate therapy in 
patients with CAD~ particular care is taken in comparing the NL data with data from 
studies conducted within the same time period. Temporal trends in prescribing patterns 
are discussed in detail Likewise the consensus guidelines used to determine appropriate 
care in these studies were published in 1996 and based on formal literature reviews from 
publications up to 1995. This should reduce the difficulty in interpreting.bias given that 
the time gap between the study treatment and treatment guidelines is small. 3) The 
NLCABG study is limited by use of retrospective chart review. Investigators were limited 
to information available from medical records. Non-documentation, misinterpretation and 
miscoding of data are particular weaknesses in this type of study. To reduce the impact of 
these problems, data were collected and analyzed by a specially trained research team 
using a Canadian tested chart abstraction instrument. After data abstraction two 
specialists independently determined appropriateness and necessity of each case using 
specific criteria developed by the RAND corporation. Nevertheless, given that risk 
adjustment is based on data from chart abstraction, the findings in this study should be 
interpreted with some caution. 
Gender bias is evident in referral for invasive cardiac intervention in these populations of 
NL patients. It is difficult to determine at what point in the referral process this difference 
occurs. Further studies are needed to see if this is applicable to the overall NL population 
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and to identey at what juncture this arises. 
83 
Appendix 1: Goldman Seale 
1. 
Could the patient walk down a flight of stairs without stopping? 
If no, go to 4. 
2. 
YN 
Could the patient carry anything up a flight of 8 steps without stopping? Y N 
Or can the patient: 
a. Have sexual intercourse without stopping 
b. Garden, rake or weed 
c. Roller skate, dance foxtrot 
d. Walk at 4 mph rate on level ground 
If no, patient is class III, go to 6. 
3. 
Could the patient carry at least 24 lb. up a flight of 8 steps? 
Or can the patient: 
a. Carry objects weighing 80 lb. 
b. Perform outdoor work (e.g. Shovel snow, spade soil) 
YN 
c. Participate in recreational activities such as skiing, basketball, touch football, 
squash, handball) 
d. Jog/walk 5 mph 
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Goldman Scale: (continued) 
If yes, patient is class I, go to 6. 
If no, patient is class II go to 6. 
4. 
Could the patient shower without stopping? 
Or can the patient: 
a. Strip and make a bed 
b. Mop floors 
c. Hang washed clothes 
d. Clean windows 
e. Walk at 2.5 mph 
f. Bowl 
g. Play golf(walk and carry clubs) 
h. Push lawn mower 
If yes, patient is class III, go to 10 
If no, go to 5. 
5. 
Could the patient dress without stopping because of symptoms? 
If yes, patient is class III, go to 6 
If no, patient is class IV, go to 6. 
6. Provide Functional Status Class: I II III 
YN 
YN 
IV 
85 
Goldman Scale: ( cootinu.ed) 
Was the limitation in activity in 1-5 above due to: 
a. Angina 
b. Dyspn~ 
c. Fatigue 
d. Physician instructions 
e. Other 
If yes, specify: --------
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Appendix 2: DefiDitiou for NLCABG Study 
Coronary artery disease: Reduction_in luminal diameter ofLeft main coronary artery of 
50% or greater by visual inspection, or reduction in lumina] diameter of one major 
coronary artery of70% or greater by visual inspection. 
Unstable angina: Chest pain thought to be due to myocardial ischemia, requiring 
hospitalization because of difficulty in control or concern about the possibility of 
myocardial infarction. This includes: (1) recent increase in intensity, frequency, or 
duration of chronic angina; (2) the development of angina at rest; or (3) new onset of 
severe chest pain ("acute coronary insufficiency"). Revascularization is carried out while 
the patient is in hospital or within 4 weeks of admission for unstable angina. 
Angina Class I: angina on strenuous exertion. 
IT: angina on walking or climbing stairs rapidly 
ITI: angina on walking one or two level blocks 
IV a: unstable angina, pain resolved with intensified medical therapy, now 
stable on oral medication 
IVb: unstable angina on oral therapy, symptoms improved but angina with 
nrinttnruprovocation 
IV c: symptoms not manageable on oral therapy, requires coronary care or 
parenteral medication, may be hemodynamically unstable 
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Significant coronary artery disease: 
a Left mam disease: Reduction in the lumina] diameter of the left main coronary artery of 
50 % or greater by visual inspection or formal calibration of angiographic findings. 
Protected left main disease is defined by the presence of a patent bypass graft to the LAD 
(left anterior descending) or circumflex arteries or by collateral flows to these arteries 
from a patent RCA (right coronary artery). 
b. Three-vessel disease: Reduction in the lumina] diameter of all three major coronary 
arteries of 50% or greater by visual inspection or calibration of angiographic findings. If 
measured by visual inspection, at least one vessel must have 80 % stenosis. The panel 
believed that these represented equivalent assessments of the extent of the diSease. 
c. Two-vessel disease: Reduction in the Juminal diameter of two major coronary arteries 
of 50% or greater by visual inspection or calibration of angiographic findings. If measured 
by visual inspection, at least one vessel must have 70 % stenosis. 
d. One-vessel disease: Reduction in the luminal diameter of one major coronary artery 
(not left main) of70% or greater by visual inspection or 50% by cah"bration. 
e. Proximal left anterior descending (PLAD): Viability of a major amount of the 
anterior wall of the left ventricles in jeopardy owing to reduction in luminal diameter of 
PLAD by 70% or greater by visual inspection ·or 50% by qualitative analyses. PLAD 
involvement that is proximal to the first septal perforator. 
Operative risk score: 
Fenude +1 
Weight> 1.5 ideal +3 
Diabetes mellitus + 3 
Systolic BP > 140 mmHG +3 
Ejection Fraction mild impairment +2 
Ejection Fraction severe impairment +4 
Age 70-74 +7 
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75-79 
?:80 
First reoperation 
Second reoperation 
Pre-op intra aortic balloon pump 
LV aneurysm 
Emergency surgery following CA or PTCA 
Dialysis dependent 
Catastrophic state 
Rare problem 
Mitral valve surgery 
PA pressure?: 60 
Aortic valve surgery 
Aortic gradient> 120 
CABO at time of valve surgery 
Chronic obstructive lung disease 
Peripheral vascular disease with 
claudication or amputation 
Symptomatic carotid artery disease 
Maximal medical therapy: 
+12 
+20 
+5 
+10 
+2 
+5 
+10 
+10 
+10-50 
+2-10 
+5 
+8 
+5 
+7 
+2 
+4 
+3 
+4 
a. Chronic stable angina: The patient has received drugs ·from at least two of the three 
major classes (nitrates, beta-blockers, and calcium antagonists) or the patient has received 
one class of medication, but there is a note in the chart that the patient is unable to tolerate 
the others. 
b. Unstable angina: Must meet one of the following criteria: 
1. The patient has received drugs from at least two of the following major classes 
of drugs: nitrates, beta-blockers, calcium antagonists, and intravenous heparin (except To 
Keep Open (TKO) Hep-lock), or 
2. Receiving intravenous nitroglycerin, or 
3. Receiving one of the three major classes of drugs (nitrates, beta-blockers, 
calcium antagonists), with a note in the chart indicating that the patient is unable to 
tolerate other drugs. 
Contraindications to CABO: 
a. Terminal illness, such as cancer, AIDS, severe COPD, hepatic failure, where a 
reasonable prognosis is six months or less. 
b. Advanced dementia. 
c. Severe impairment in ability to perform basic activities of daily living (Katz score of~ 
3/6) because ofnoncardiac disease. 
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SCORING SYSTEM FOR RANKING RELATIVE URGENCE OF NEED FOR 
REVASCULARJZATION 
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